



28 OCT 2003

708/8003/00144
BE03/0441

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 28 OCT 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.





Signed

Dated 5 September 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Best Available Copy



Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

L RD - GB - 4 - 421

2. Patent application number

(The Patent Office will fill in this part)

0309521.3

25 APR 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Rege Foundation

7893589001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

5. Name of your agent (if you have one)

KU Leuven

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

8049165002

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

12. Name and daytime telephone number of person to contact in the United Kingdom

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

49

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

1 fax cover sheet

1 fee sheet with request for fax back service

11.

I/We request the grant of a patent on the basis of this application.

Prof. Dr. Erik De Clercq

Signature

Date

24 April 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Hubert Velge
+44 7940 540 397

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0845 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Glycopeptide Analogues

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

- 10 The field of the invention comprises novel pharmaceuticals for preventing and treating antiviral infection, preferably retroviral infections and more preferably HIV infection.

BACKGROUND

- 15 Glycopeptide antibiotics (Vancomycin, Teicoplanin) are vital therapeutic agents used worldwide for the treatment of infections with gram-positive bacteria. Emerging bacterial resistance to vancomycin, which has recently become a major public health threat, is a stimulus for the synthesis and investigation of various derivatives of glycopeptide antibiotics (Malabarba, A et al Med. Res. Rev. 17: 69-137, 1997 and Pavlov A.Y. & M.N.Preobrazhenskaya. Russian
20 Journal of Bioorganic Chemistry. 24:570 - 587, 1998). However, none of these compounds or their derivatives have been demonstrated to have antiviral properties or to be suitable to inhibit or prevent viral infections.

- The present invention includes various semisynthetic derivatives of natural glycopeptide
25 antibiotics such as vancomycin, eremomycin, chloreremomycin, teicoplanin, DA-40926 and others, their aglycons and also products of their partial degradation with the peptide core destroyed or modified in peptide core and in sugar moieties. The present derivatives are useful as anti-HIV compounds. They are particularly effective against drug-resistant HIV strains.

30 **SUMMARY OF THE INVENTION**


Semisynthetic derivatives of natural glycopeptide antibiotics have been designed and tested for antiviral activity and cell toxicity.

The invention includes compounds and methods of making compounds with pronounced anti-HIV activity and low cell toxicity, methods of structurally modifying said compounds for enhanced antiviral activity and methods of structurally modifying said compounds for decreasing or removing antibacterial activity while maintaining antiviral activity.


An embodiment of present invention comprises thus pharmaceuticals derived from glycopeptide antibiotics or from glycopeptides with an analogue structure for preventing and treating antiviral infection, preferably retroviral infections and more preferably HIV infection.

A preferred embodiment of present invention are compounds of the formula I, II and III


Formula I



Formula II



Formula III



wherein:

- 5 b^1 and b^2 each independently represents nihil or an additional bond, R^0 represents nihil when b^2 represents an additional bond and hydrogen when b^2 represents nihil, R^6 represents nihil when b^1 represents an additional bond and hydrogen when b^1 represents nihil, R^6 represents R^{6a} and R^0 represents hydrogen when b^1 and b^2 each represents nihil, wherein R^{6a} is described below. Preferably R^6 represents R^{6a} , R^0 represents hydrogen and b^1 and b^2 each represents nihil;

10

b^3 represents nihil or an additional bond, R^a --- R^{5a} represents a group of the formula: $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_zN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_zN(R^{11a})CO$ when b^3 represents an additional bond, and R^a is R and R^{5a} is R^5 when b^3 represents nihil, wherein z is 0, 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below. Preferably R^a --- R^{5a} represents

15

$CHNHCO$; b^4 represents nihil or an additional bond, R^b --- R^{5b} represents a group of the formula: $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_pN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_pN(R^{11a})CO$ when b^4 represents an additional bond, and R^b is R and R^{5b} is R^5 when b^4 represents nihil, wherein p is 0, 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below;

20

b^5 , b^6 and b^7 each independently represents nihil or an additional bond. Y represents oxygen, R^{6a} represents hydrogen and R^d represents R or a group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 and b^7 represent nihil and b^6 represents an additional bond. R^{6a} represents nihil, R^d --- Y represents a group of the formula: $CHN=C(NR^{11})O$ or $CHNHCON(R^{11})$ when b^6 represents nihil and b^5 represents an additional

bond. Y and R^{0a} each represents a hydrogen and R^d represents group of the formula: (CH₂)_qCON(R¹¹)CH(CH₂OH) (CH₂)_qN(R¹²)CH(CH₂OH) when b⁵, b⁶ and b⁷ each represents nihil, wherein q is 0, 1, 2, or 3 and R, R¹¹ and R¹² are described below;

n is 0, 1, 2 or 3;

- 5 X¹, X², X³, X⁴, X⁵, X⁷ and X⁹ are each independently selected from hydrogen, halogen and X⁶, wherein X⁶ is defined below. Preferably X¹, X², X³, X⁴, X⁵, X⁷ and X⁹ are each independently selected from hydrogen and Cl;

X⁶ is selected from the group comprising hydrogen, halogen, SO₃H, OH, NO, NO₂, NHNH₂, NHN=CHR¹¹, N=NR¹¹, CHR¹¹R¹³, CH₂N(R³)R¹¹, R⁵, R¹¹ and R¹³, wherein R³ is CH₂ attached
10 to phenolic hydroxyl group of the 7th amino acid, R⁴, R¹¹ and R¹³ are defined below. Preferably X⁶ is CH₂R¹³;

X⁸ is selected from hydrogen and methyl;

R^c represents R and R⁵⁰ represents R⁵, wherein R and R⁵ are defined below;

R is selected from CHR¹³ and R¹⁴, wherein R¹³ and R¹⁴ are defined below. Preferably R is
15 CHR¹³;

R¹ is selected from hydrogen and R¹¹, wherein R¹¹ is defined below. Preferably R¹ is (CH₂)_tCOOH, (CH₂)_tCONR¹¹R¹², (CH₂)_tCOR¹³, (CH₂)_tCOOR¹¹, COR¹⁵, (CH₂)_tOH, (CH₂)_tCN, (CH₂)_tR¹³, (CH₂)_tSCH₃, (CH₂)_tSOCH₃, (CH₂)_tS(O)₂CH₃, (CH₂)_tphenyl(*m*-OH, *p*-Cl), (CH₂)_tphenyl(*o*-X⁷, *m*-OR¹⁰, *p*-X³)-[O-phenyl(*o*-OR⁹, *m*-X⁹, *m*-R¹⁶)]-*m*, where t is 0, 1, 2, 3 or
20 4. R, X⁷, X⁸, X⁹ are defined above. R¹¹, R¹², R¹³, R¹⁵ and R¹⁶ are defined below;

R² and R⁴ are each independently selected from hydrogen, R¹² and R¹⁷, wherein R¹² and R¹⁷ are defined below;

R³ is selected from hydrogen, R¹², R¹⁷ or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or O-acetylmannosyl. R¹² and R¹⁷ are defined below;

- 25 R⁵ is selected from COOH, COOR¹¹, COR¹³, COR¹⁵, CH₂OH, CH₂halogen, CH₂R¹³, CHO, CH=NOR¹¹, CH=NNR¹¹R¹² and C=NNHCONR¹¹R¹², wherein R¹¹, R¹², R¹³ and R¹⁵ are defined below;

R^{6a} is selected from OR¹², OR¹⁷, OH, O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-
30 vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucurony, 4-oxovancosaminy, ureido-4-oxovancosaminy and their derivatives with functional groups such as, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising NR¹¹R¹², N⁺R¹¹R^{11a}R^{11b}, COOR¹¹, COR¹³, COR¹⁵, O-R¹², O-R¹⁷, C=NOR¹¹,

CHNHOR¹¹, C=NNR¹¹R¹² and C=NNHCONR¹¹R¹² derivatives, wherein R¹¹, R^{11a}, R^{11b}, R¹², R¹³, R¹⁵ and R¹⁷ are defined below;

R⁷ is selected from hydrogen, R¹², R¹⁷, Sug and alkyl-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-acylglucuronyl, glucosaminy, glucuronyl, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-olivoyl, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-4-oxovancosaminy, glucosyl(rhamnosyl)-mannosyl-arabinosyl, glucosyl-2-O-Leu and their derivatives with as functional groups, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising NR¹¹R¹², N⁺R¹¹R^{11a}R^{11b}, COOR¹¹, COR¹³, COR¹⁵, O-R¹², O-R¹⁷, C=NOR¹¹, CHNHOR¹¹, C=NNR¹¹R¹² and C=NNHCONR¹¹R¹² derivatives, wherein R¹¹, R^{11a}, R^{11b}, R¹², R¹³, R¹⁵ and R¹⁷ are defined below;

R⁸ is selected from hydrogen, R¹², R¹⁷, OH, O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is O-mannosyl, O-galactosyl and O-galactosyl-galactosyl;

R⁹ is selected from hydrogen, R¹², R¹⁷ or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is galactosyl or galactosyl-galactosyl. R¹² and R¹⁷ are defined below;

R¹⁰ is selected from hydrogen, R¹², R¹⁷ or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or fucosyl. R¹² and R¹⁷ are defined below;

R¹¹, R^{11a} and R^{11b} are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cyloalkyl, heterocycloalkyl;

R¹² and R^{12a} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, acyl, amino-protecting group, carbamoyl, thiocarbamoyl, SO₂R¹¹, S(O)R¹¹, COR¹³-R¹⁸, COCHR¹⁸N(NO)R¹¹, COCHR¹⁸NR¹¹R¹² and COCHR¹⁸N⁺R¹¹R^{11a}R^{11b}, wherein R¹¹, R^{11a} and R^{11b} are defined above, R¹³ and R¹⁸ are defined below. Preferably R^{12a} is hydrogen, COCHR¹⁸NR¹¹R¹², COCHR¹⁸N(NO)R¹¹,

COCHR¹⁸N⁺R¹¹R^{11a}R^{11b} and COCHR¹⁸R¹³;

R¹³ is selected from the group consisting of hydrogen, NHR^{12a}, NR¹¹R¹², NR¹¹Sug, N⁺R¹¹R^{11a}R^{11b}, R¹⁵, NR¹¹C(R^{11a}R^{11b})COR¹⁵ and group of the formula:

N- A- N⁺- A

wherein A is $-\text{CH}_2\text{-B-CH}_2\text{-}$ and B is $-(\text{CH}_2)_m\text{-D-}(\text{CH}_2)_r\text{-}$, wherein m and r are from 1 to 4 and D is O, S, NR^{12} , $\text{N}^+\text{R}^{11}\text{R}^{11a}$, wherein Sug is any cyclic or acyclic carbohydrate, R^{11} , R^{11a} and R^{12} are defined above;

R^{14} is CH_2 , C=O , CHOH , C=NOR^{11} , CHNHOR^{11} , $\text{C=NNR}^{11}\text{R}^{12}$, $\text{C=NNHCONR}^{11}\text{R}^{12}$ and

5 $\text{CHNHNR}^{11}\text{R}^{12}$, wherein R^{11} and R^{12} are defined above;

R^{15} is selected from $\text{N(R}^{11})\text{NR}^{11a}\text{R}^{12}$, $\text{N(R}^{11})\text{OR}^{11a}$, $\text{NR}^{11}\text{C(R}^{11a}\text{R}^{11b})\text{COR}^{13}$, wherein R^{11} , R^{11a} , R^{11b} , R^{12} and R^{13} are defined above;

R^{16} is selected from group of the formula: R-R^5 or $\text{CH(NH}_2\text{)CH}_2\text{OH}$;

R^{17} is selected from SO_3H , $\text{SiR}^{11}\text{R}^{11a}\text{R}^{11b}$, $\text{SiOR}^{11}\text{OR}^{11a}\text{OR}^{11b}$, $\text{PR}^{11}\text{R}^{11a}$, $\text{P(O)R}^{11}\text{R}^{11a}$,

10 $\text{P}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above;


R^{18} is selected from hydrogen and R^1 , wherein R^1 is defined above. Preferably R^{18} is CH_3 , $\text{CH}_2\text{CH(CH}_3\text{)}_2$, phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, phenyl-O-methylrhamnose-*p*;

15 or a pharmaceutically acceptable salt thereof, for use in a therapeutic treatment or prophylactic treatment of viral infection


A more preferred embodiment of present invention is the use of compounds of the formula I, II and III

20


Formula I



Formula II



Formula III



5

wherein:

b¹ and b² each independently represents nihil or an additional bond, R⁰ represents nihil when b² represents an additional bond and hydrogen when b² represents nihil, R⁶ represents nihil when b¹ represents an additional bond and hydrogen when b¹ represents nihil, R⁶ represents R^{6a} and R⁰ represents hydrogen when b¹ and b² each represents nihil, wherein R^{6a} is described below. Preferably R⁶ represents R^{6a}, R⁰ represents hydrogen and b¹ and b² each represents nihil;

15 b^3 represents nihil or an additional bond, R^a-R^{5a} represents a group of the formula:
 $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_2N(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_2N(R^{11a})CO$ when b^3
represents an additional bond, and R^a is R and R^{5a} is R^5 when b^3 represents nihil, wherein z is 0,
1, 2, 3 or 4 and R, R^5 , R^{11} and R^{11a} are described below. Preferably R^a-R^{5a} represents
 $CHNHCO$:

b^4 represents nihil or an additional bond, R^b-R^{5b} represents a group of the formula: $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_2N(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_pN(R^{11a})CO$ when b^4 represents an additional bond, and R^b is R and R^{5b} is R^5 when b^4 represents nihil, wherein p is 0, 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below;

- 5 b^5 , b^6 and b^7 each independently represents nihil or an additional bond. Y represents oxygen, R^{0a} represents hydrogen and R^d represents R or a group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 and b^7 represent nihil and b^6 represents an additional bond. R^{0a} represents nihil, R^d-Y represents a group of the formula: $CHN=C(NR^{11})O$ or $CHNHCON(R^{11})$ when b^6 represents nihil and b^5 represents an additional bond. Y and R^{0a} each represents a hydrogen and R^d represents group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 , b^6 and b^7 each represents nihil, wherein q is 0, 1, 2, or 3 and R , R^{11} and R^{12} are described below;

n is 0, 1, 2 or 3;

X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen, halogen and X^6 ,

- 15 wherein X^6 is defined below. Preferably X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen and Cl;

X^6 is selected from the group comprising hydrogen, halogen, SO_3H , OH , NO , NO_2 , $NHNH_2$, $NHN=CHR^{11}$, $N=NR^{11}$, $CHR^{11}R^{13}$, $CH_2N(R^3)R^{11}$, R^5 , R^{11} and R^{13} , wherein R^3 is CH_2 attached to phenolic hydroxyl group of the 7th amino acid, R^5 , R^{11} and R^{13} are defined below. Preferably

- 20 X^6 is CH_2R^{13} ;

X^8 is selected from hydrogen and methyl;

R^a represents R and R^{5a} represents R^5 , wherein R and R^5 are defined below;

R is selected from CHR^{13} and R^{14} , wherein R^{13} and R^{14} are defined below. Preferably R is CHR^{13} ;

- 25 R^1 is selected from hydrogen and R^{11} , wherein R^{11} is defined below. Preferably R^1 is $(CH_2)_tCOOH$, $(CH_2)_tCONR^{11}R^{12}$, $(CH_2)_tCOR^{13}$, $(CH_2)_tCOOR^{11}$, COR^{15} , $(CH_2)_tOH$, $(CH_2)_tCN$, $(CH_2)_tR^{13}$, $(CH_2)_tSCH_3$, $(CH_2)_tSOCH_3$, $(CH_2)_tS(O)_2CH_3$, $(CH_2)_tphenyl(m-OH, p-Cl)$, $(CH_2)_tphenyl(o-X^7, m-OR^{10}, p-X^8)-[O-phenyl(o-OR^9, m-X^9, m-R^{16})]-m$, where t is 0, 1, 2, 3 or 4. R , X^7 , X^8 , X^9 are defined above. R^{11} , R^{12} , R^{13} , R^{15} and R^{16} are defined below;

- 30 R^2 and R^4 are each independently selected from hydrogen, R^{12} and R^{17} , wherein R^{12} and R^{17} are defined below;

R^3 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or O-acetylmannosyl. R^{12} and R^{17} are defined below;

R^5 is selected from COOH , COOR^{11} , COR^{13} , COR^{15} , CH_2OH , $\text{CH}_2\text{halogen}$, CH_2R^{13} , CHO , $\text{CH}=\text{NOR}^{11}$, $\text{CH}=\text{NNR}^{11}\text{R}^{12}$ and $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$, wherein R^{11} , R^{12} , R^{13} and R^{15} are defined below;

R^{6a} is selected from OR^{12} , OR^{17} , OH , O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucurony, 4-oxovancosaminy, ureido-4-oxovancosaminy and their derivatives with functional groups such as for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $\text{NR}^{11}\text{R}^{12}$, $\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, COOR^{11} , COR^{13} , COR^{15} , O-R^{12} , O-R^{17} , $\text{C}=\text{NOR}^{11}$, CHNHOR^{11} , $\text{C}=\text{NNR}^{11}\text{R}^{12}$ and $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

R^7 is selected from hydrogen, R^{12} , R^{17} , Sug and alkyl-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-acylglucurony, glucosaminy, glucurony, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-olivony, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-4-oxovancosaminy, glucosyl(rhamnosyl)-mannosyl-arabiny, glucosyl-2-O-Leu and their derivatives with as functional groups, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $\text{NR}^{11}\text{R}^{12}$, $\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, COOR^{11} , COR^{13} , COR^{15} , O-R^{12} , O-R^{17} , $\text{C}=\text{NOR}^{11}$, CHNHOR^{11} , $\text{C}=\text{NNR}^{11}\text{R}^{12}$ and $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

R^8 is selected from hydrogen, R^{12} , R^{17} , OH , O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is O-mannosyl, O-galactosyl and O-galactosyl-galactosyl;


R^9 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is galactosyl or galactosyl-galactosyl. R^{12} and R^{17} are defined below;

R^{10} is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or fucosyl. R^{12} and R^{17} are defined below;

R^{11} , R^{11a} and R^{11b} are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cyloalkyl, heterocycloalkyl;

R^{12} and R^{12a} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, acyl, amino-protecting group, carbamoyl, thiocarbamoyl, SO_2R^{11} , $S(O)R^{11}$, $COR^{13}-R^{18}$, $COCHR^{18}N(NO)R^{11}$, $COCHR^{18}NR^{11}R^{12}$ and $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above, R^{13} and R^{18} are defined below. Preferably R^{12a} is hydrogen, $COCHR^{18}NR^{11}R^{12}$, $COCHR^{18}N(NO)R^{11}$, $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$ and $COCHR^{18}R^{13}$;

R^{13} is selected from the group consisting of hydrogen, NHR^{12a} , $NR^{11}R^{12}$, $NR^{11}Sug$, $N^+R^{11}R^{11a}R^{11b}$, R^{15} , $NR^{11}C(R^{11a}R^{11b})COR^{15}$ and group of the formula:



wherein A is $-CH_2-B-CH_2-$ and B is $-(CH_2)_m-D-(CH_2)_r-$, wherein m and r are from 1 to 4 and D is O, S, NR^{12} , $N^+R^{11}R^{11a}$, wherein Sug is any cyclic or acyclic carbohydrate, R^{11} , R^{11a} and R^{12} are defined above;

R^{14} is CH_2 , $C=O$, $CHOH$, $C=NOR^{11}$, $CHNHOR^{11}$, $C=NNR^{11}R^{12}$, $C=NNHCONR^{11}R^{12}$ and $CHNHNR^{11}R^{12}$, wherein R^{11} and R^{12} are defined above;

R^{15} is selected from $N(R^{11})NR^{11a}R^{12}$, $N(R^{11})OR^{11a}$, $NR^{11}C(R^{11a}R^{11b})COR^{13}$, wherein R^{11} , R^{11a} , R^{11b} , R^{12} and R^{13} are defined above;

R^{16} is selected from group of the formula: $R-R^5$ or $CH(NH_2)CH_2OH$;

R^{17} is selected from SO_3H , $SiR^{11}R^{11a}R^{11b}$, $SiOR^{11}OR^{11a}OR^{11b}$, $PR^{11}R^{11a}$, $P(O)R^{11}R^{11a}$, $P^+R^{11}R^{11a}R^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above;


R^{18} is selected from hydrogen and CH_3 , wherein R^{11} is defined above. R^{12} is CH_3 , $CH_2CH(CH_3)_2$, phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, phenyl-O-methylrhamnose-*p*;

or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for preventing or treating viral infections.

Each compound of the present invention may be a pure stereoisomer coupled at each of its chiral centers or it may be inverted at one or more of its chiral centers. It may be a single stereoisomer or a mixture of two or more stereoisomers. If it is a mixture, the ratio may or may not be equimolar. Preferably the compound is a single stereoisomer. Preferably the stereochemistry of the peptide core of the compound containing six amino acids (2-7) is 2(*R*), 3(*S*), 4(*R*), 5(*R*), 6(*S*) and 7(*S*).


Yet another preferred embodiment of present invention are compounds of the formula I, II and III

Formula I




3

Formula II



Formula III

10



wherein:

- 5 b^1 and b^2 each independently represents nihil or an additional bond, R^0 represents nihil when b^2 represents an additional bond and hydrogen when b^2 represents nihil, R^6 represents nihil when b^1 represents an additional bond and hydrogen when b^1 represents nihil, R^6 represents R^{6a} and R^0 represents hydrogen when b^1 and b^2 each represents nihil, wherein R^{6a} is described below. Preferably R^6 represents R^{6a} , R^0 represents hydrogen and b^1 and b^2 each represents nihil;

- 10 b^3 represents nihil or an additional bond, R^a---R^{3a} represents a group of the formula: $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_zN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_zN(R^{11a})CO$ when b^3 represents an additional bond, and R^a is R and R^{3a} is R^5 when b^3 represents nihil, wherein z is 0, 1, 2, 3 or 4 and R, R^5 , R^{11} and R^{11a} are described below. Preferably R^a---R^{5a} represents $CHNHCO$;

- 15 b^4 represents nihil or an additional bond, R^b---R^{5b} represents a group of the formula: $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_pN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_pN(R^{11a})CO$ when b^4 represents an additional bond, and R^b is R and R^{5b} is R^5 when b^4 represents nihil, wherein p is 0, 1, 2, 3 or 4 and R, R^5 , R^{11} and R^{11a} are described below;

- 20 b^5 , b^6 and b^7 each independently represents nihil or an additional bond. Y represents oxygen, R^{0a} represents hydrogen and R^d represents R or a group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 and b^7 represent nihil and b^6 represents an additional bond. R^{0a} represents nihil, R^d---Y represents a group of the formula: $CHN=C(NR^{11})O$ or $CHNHCON(R^{11})$ when b^6 represents nihil and b^5 represents an additional bond. Y and R^{0a} each represents a hydrogen and R^d represents group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 , b^6 and b^7 each represents nihil, wherein q is 0, 1, 2, or 3 and R, R^{11} and R^{12} are described below;
- 25 n is 0, 1, 2 or 3;

X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen, halogen and X^6 , wherein X^6 is defined below. Preferably X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen and Cl;

- 30 X^6 is selected from the group comprising hydrogen, halogen, SO_3H , OH, NO, NO_2 , $NHNH_2$, $NHN=CHR^{11}$, $N=NR^{11}$, $CHR^{11}R^{13}$, $CH_2N(R^3)R^{11}$, R^5 , R^{11} and R^{13} , wherein R^3 is CH_2 attached to phenolic hydroxyl group of the 7th amino acid, R^5 , R^{11} and R^{13} are defined below. Preferably X^6 is CH_2R^{13} ;

X^8 is selected from hydrogen and methyl;

R^c represents R and R^{5c} represents R^5 , wherein R and R^5 are defined below;

R is selected from CHR^{13} and R^{14} , wherein R^{13} and R^{14} are defined below. Preferably R is CHR^{13} ;

5 R^1 is selected from hydrogen and R^{11} , wherein R^{11} is defined below. Preferably R^1 is $(CH_2)_tCOOH$, $(CH_2)_tCONR^{11}R^{12}$, $(CH_2)_tCOR^{13}$, $(CH_2)_tCOOR^{11}$, COR^{15} , $(CH_2)_tOH$, $(CH_2)_tCN$, $(CH_2)_tR^{13}$, $(CH_2)_tSCH_3$, $(CH_2)_tSOCH_3$, $(CH_2)_tS(O)_2CH_3$, $(CH_2)_t$ phenyl(*m*-OH, *p*-Cl), $(CH_2)_t$ phenyl(*o*- X^7 , *m*- OR^{10} , *p*- X^8)-[O-phenyl(*o*- OR^9 , *m*- X^9 , *m*- R^{16})]-*m*, where *t* is 0, 1, 2, 3 or 4. R , X^7 , X^8 , X^9 are defined above. R^{11} , R^{12} , R^{13} , R^{15} and R^{16} are defined below;

10 R^2 and R^4 are each independently selected from hydrogen, R^{12} and R^{17} , wherein R^{12} and R^{17} are defined below;

R^3 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or O-acetylmannosyl. R^{12} and R^{17} are defined below;

R^5 is selected from $COOH$, $COOR^{11}$, COR^{13} , COR^{15} , CH_2OH , CH_2 halogen, CH_2R^{13} , CHO ,

15 $CH=NOR^{11}$, $CH=NNR^{11}R^{12}$ and $C=NNHCONR^{11}R^{12}$, wherein R^{11} , R^{12} , R^{13} and R^{15} are defined below;

R^{6a} is selected from OR^{12} , OR^{17} , OH , O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucurony, 4-oxovancosaminy, ureido-4-oxovancosaminy and their derivatives with functional groups such as, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $NR^{11}R^{12}$, $N^+R^{11}R^{11a}R^{11b}$, $COOR^{11}$, COR^{13} , COR^{15} , O- R^{12} , O- R^{17} , $C=NOR^{11}$, $CHNHOR^{11}$, $C=NNR^{11}R^{12}$ and $C=NNHCONR^{11}R^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

25 R^7 is selected from hydrogen, R^{12} , R^{17} , Sug and alkyl-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-acylglucurony, glucosaminy, glucurony, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, 30 glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-olivoyl, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-4-oxovancosaminy, glucosyl(rhamnosyl)-mannosyl-arabiny, glucosyl-2-O-Leu and their derivatives with as functional groups, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $NR^{11}R^{12}$,

$N^+R^{11}R^{11a}R^{11b}$, $COOR^{11}$, COR^{13} , COR^{15} , $O-R^{12}$, $O-R^{17}$, $C=NOR^{11}$, $CHNHOR^{11}$, $C=NNR^{11}R^{12}$ and $C=NNHCONR^{11}R^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

R^8 is selected from hydrogen, R^{12} , R^{17} , OH , O -alkyl-Sug and O -Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is O -mannosyl, O -galactosyl and O -galactosyl-galactosyl;


R^9 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is galactosyl or galactosyl-galactosyl. R^{12} and R^{17} are defined below;

R^{10} is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or fucosyl. R^{12} and R^{17} are defined below;

R^{11} , R^{11a} and R^{11b} are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl;

R^{12} and R^{12a} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, acyl, amino-protecting group, carbamoyl, thiocarbamoyl, SO_2R^{11} , $S(O)R^{11}$, $COR^{13}-R^{18}$, $COCHR^{18}N(NO)R^{11}$, $COCHR^{18}NR^{11}R^{12}$ and $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above, R^{13} and R^{18} are defined below. Preferably R^{12a} is hydrogen, $COCHR^{18}NR^{11}R^{12}$, $COCHR^{18}N(NO)R^{11}$, $COCHR^{18}N^+R^{11}R^{11a}R^{11b}$ and $COCHR^{18}R^{13}$;

R^{13} is selected from the group consisting of hydrogen, NHR^{12a} , $NR^{11}R^{12}$, $NR^{11}Sug$, $N^+R^{11}R^{11a}R^{11b}$, R^{15} , $NR^{11}C(R^{11a}R^{11b})COR^{15}$ and group of the formula:



wherein A is $-CH_2-B-CH_2-$ and B is $-(CH_2)_m-D-(CH_2)_r-$, wherein m and r are from 1 to 4 and D is O, S, NR^{12} , $N^+R^{11}R^{11a}$, wherein Sug is any cyclic or acyclic carbohydrate, R^{11} , R^{11a} and R^{12}

are defined above;

R^{14} is CH_2 , $C=O$, $CHOH$, $C=NOR^{11}$, $CHNHOR^{11}$, $C=NNR^{11}R^{12}$, $C=NNHCONR^{11}R^{12}$ and $CHNHNR^{11}R^{12}$, wherein R^{11} and R^{12} are defined above;

R^{15} is selected from $N(R^{11})NR^{11a}R^{12}$, $N(R^{11})OR^{11a}$, $NR^{11}C(R^{11a}R^{11b})COR^{13}$, wherein R^{11} , R^{11a} , R^{11b} , R^{12} and R^{13} are defined above;

R^{16} is selected from group of the formula: $R-R^5$ or $CH(NH_2)CH_2OH$;


R^{17} is selected from SO_3H , $SIR^{11}R^{11a}R^{11b}$, $SIOR^{11}OR^{11a}OR^{11b}$, $PR^{11}R^{11a}$, $P(O)R^{11}R^{11a}$, $P^+R^{11}R^{11a}R^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above;

R^{18} is selected from hydrogen and R^1 , wherein R^1 is defined above. Preferably R^{18} is CH_3 , $CH_2CH(CH_3)_2$, phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, phenyl-O-methylrhamnose-*p*;


5 or a pharmaceutically acceptable salt thereof, for use in a treatment or preventive treatment of HIV infection, or of AIDS or of AIDS related complex.


10 Yet another preferred embodiment of present invention is the use of compounds of the formula I, II and III

Formula I



15 Formula II





wherein:

- b^1 and b^2 each independently represents nihil or an additional bond, R^0 represents nihil when b^2 represents an additional bond and hydrogen when b^2 represents nihil, R^6 represents nihil when b^1 represents an additional bond and hydrogen when b^1 represents nihil, R^6 represents R^{6a} and R^0 represents hydrogen when b^1 and b^2 each represents nihil, wherein R^{6a} is described below. Preferably R^6 represents R^{6a} , R^0 represents hydrogen and b^1 and b^2 each represents nihil;

- b^3 represents nihil or an additional bond, R^a---R^{5a} represents a group of the formula:
 $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_zN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_zN(R^{11a})CO$ when b^3 represents an additional bond, and R^a is R and R^{5a} is R^5 when b^3 represents nihil, wherein z is 0, 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below. Preferably R^a---R^{5a} represents $CHNHCO$;

- b^4 represents nihil or an additional bond, R^b---R^{5b} represents a group of the formula:
 $CHN(R^{11})CO$, $CHN(R^{11})(CH_2)_pN(R^{11a})CO$ or $CHN(R^{11})CO(CH_2)_pN(R^{11a})CO$ when b^4 represents an additional bond, and R^b is R and R^{5b} is R^5 when b^4 represents nihil, wherein p is 0, 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below;

- b^5 , b^6 and b^7 each independently represents nihil or an additional bond. Y represents oxygen, R^{0a} represents hydrogen and R^d represents R or a group of the formula:
 $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 and b^7 represent nihil and b^6 represents an additional bond. R^{0a} represents nihil, R^d---Y represents a group of the formula:
 $CHN=C(NR^{11})O$ or $CHNHCON(R^{11})$ when b^6 represents nihil and b^5 represents an additional bond. Y and R^{0a} each represents a hydrogen and R^d represents group of the formula:

$(\text{CH}_2)_q\text{CON}(\text{R}^{11})\text{CH}(\text{CH}_2\text{OH})$ $(\text{CH}_2)_q\text{N}(\text{R}^{12})\text{CH}(\text{CH}_2\text{OH})$ when b^5 , b^6 and b^7 each represents nihil, wherein q is 0, 1, 2, or 3 and R , R^{11} and R^{12} are described below;

n is 0, 1, 2 or 3;

- 5 X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen, halogen and X^6 , wherein X^6 is defined below. Preferably X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen and Cl;

X^6 is selected from the group comprising hydrogen, halogen, SO_3H , OH , NO , NO_2 , NHNH_2 , NHN=CHR^{11} , N=NR^{11} , $\text{CHR}^{11}\text{R}^{13}$, $\text{CH}_2\text{N}(\text{R}^3)\text{R}^{11}$, R^5 , R^{11} and R^{13} , wherein R^3 is CH_2 attached to phenolic hydroxyl group of the 7th amino acid, R^5 , R^{11} and R^{13} are defined below. Preferably

- 10 X^6 is CH_2R^{13} ;

X^8 is selected from hydrogen and methyl;

R^c represents R and R^{5c} represents R^5 , wherein R and R^5 are defined below;

R is selected from CHR^{13} and R^{14} , wherein R^{13} and R^{14} are defined below. Preferably R is CHR^{13} ;

- 15 R^1 is selected from hydrogen and R^{11} , wherein R^{11} is defined below. Preferably R^1 is $(\text{CH}_2)_t\text{COOH}$, $(\text{CH}_2)_t\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_t\text{COR}^{13}$, $(\text{CH}_2)_t\text{COOR}^{11}$, COR^{15} , $(\text{CH}_2)_t\text{OH}$, $(\text{CH}_2)_t\text{CN}$, $(\text{CH}_2)_t\text{R}^{13}$, $(\text{CH}_2)_t\text{SCH}_3$, $(\text{CH}_2)_t\text{SOCH}_3$, $(\text{CH}_2)_t\text{S}(\text{O})_2\text{CH}_3$, $(\text{CH}_2)_t\text{phenyl}(m\text{-OH}, p\text{-Cl})$, $(\text{CH}_2)_t\text{phenyl}(o\text{-X}^7, m\text{-OR}^{10}, p\text{-X}^8)\text{-[O-phenyl}(o\text{-OR}^9, m\text{-X}^9, m\text{-R}^{16})\text{]-}m$, where t is 0, 1, 2, 3 or 4. R , X^7 , X^8 , X^9 are defined above. R^{11} , R^{12} , R^{13} , R^{15} and R^{16} are defined below;

- 20 R^2 and R^4 are each independently selected from hydrogen, R^{12} and R^{17} , wherein R^{12} and R^{17} are defined below;

R^3 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or O-acetylmannosyl. R^{12} and R^{17} are defined below;

R^5 is selected from COOH , COOR^{11} , COR^{13} , COR^{15} , CH_2OH , $\text{CH}_2\text{halogen}$, CH_2R^{13} , CHO ,

- 25 CH=NOR^{11} , $\text{CH=NNR}^{11}\text{R}^{12}$ and $\text{C=NNHCONR}^{11}\text{R}^{12}$, wherein R^{11} , R^{12} , R^{13} and R^{15} are defined below;

R^{6a} is selected from OR^{12} , OR^{17} , OH , O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucurony, 4-

- 30 oxovancosaminy, ureido-4-oxovancosaminy and their derivatives with functional groups such as, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $\text{NR}^{11}\text{R}^{12}$, $\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, COOR^{11} , COR^{13} , COR^{15} , O-R^{12} , O-R^{17} , C=NOR^{11} ,

CHNHOR¹¹, C=NNR¹¹R¹² and C=NNHCONR¹¹R¹² derivatives, wherein R¹¹, R^{11a}, R^{11b}, R¹², R¹³, R¹⁵ and R¹⁷ are defined below;

R⁷ is selected from hydrogen, R¹², R¹⁷, Sug and alkyl-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-

5 acylglucuronyl, glucosaminy, glucuronyl, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-oliviosyl, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-4-oxovancosaminy, glucosyl(rhamnosyl)-mannosyl-

10 arabinosyl, glucosyl-2-O-Leu and their derivatives with functional groups such as, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising NR¹¹R¹², N⁺R¹¹R^{11a}R^{11b}, COOR¹¹, COR¹³, COR¹⁵, O-R¹², O-R¹⁷, C=NOR¹¹, CHNHOR¹¹, C=NNR¹¹R¹² and C=NNHCONR¹¹R¹² derivatives, wherein R¹¹, R^{11a}, R^{11b}, R¹², R¹³, R¹⁵ and R¹⁷ are defined below;

15 R⁸ is selected from hydrogen, R¹², R¹⁷, OH, O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is O-mannosyl, O-galactosyl and O-galactosyl-galactosyl;

R⁹ is selected from hydrogen, R¹², R¹⁷ or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is galactosyl or galactosyl-galactosyl. R¹² and R¹⁷ are defined

20 below;

R¹⁰ is selected from hydrogen, R¹², R¹⁷ or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or fucosyl. R¹² and R¹⁷ are defined below;

R¹¹, R^{11a} and R^{11b} are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cyloalkyl, heterocycloalkyl;

25 R¹² and R^{12a} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, acyl, amino-protecting group, carbamoyl, thiocarbamoyl, SO₂R¹¹, S(O)R¹¹, COR¹³-R¹⁸, COCHR¹⁸N(NO)R¹¹, COCHR¹⁸NR¹¹R¹² and COCHR¹⁸N⁺R¹¹R^{11a}R^{11b}, wherein R¹¹, R^{11a} and R^{11b} are defined above, R¹³ and R¹⁸ are defined below. Preferably R^{12a} is hydrogen, COCHR¹⁸NR¹¹R¹², COCHR¹⁸N(NO)R¹¹,

30 COCHR¹⁸N⁺R¹¹R^{11a}R^{11b} and COCHR¹⁸R¹³;

R¹³ is selected from the group consisting of hydrogen, NHR^{12a}, NR¹¹R¹², NR¹¹Sug, N⁺R¹¹R^{11a}R^{11b}, R¹⁵, NR¹¹C(R^{12a}R^{11b})COR¹⁵ and group of the formula:

N-A- N⁺- A

wherein A is $-\text{CH}_2-\text{B}-\text{CH}_2-$ and B is $-(\text{CH}_2)_m-\text{D}-(\text{CH}_2)_r-$, wherein m and r are from 1 to 4 and D is O, S, NR^{12} , $\text{N}^+\text{R}^{11}\text{R}^{11a}$, wherein Sug is any cyclic or acyclic carbohydrate, R^{11} , R^{11a} and R^{12} are defined above;

R^{14} is CH_3 , $\text{C}=\text{O}$, CHOH , $\text{C}=\text{NOR}^{11}$, CHNHOR^{11} , $\text{C}=\text{NNR}^{11}\text{R}^{12}$, $\text{C}=\text{NNHCONR}^{11}\text{R}^{12}$ and $\text{C}(\text{NH})\text{NR}^{11}\text{R}^{12}$, wherein R^{11} and R^{12} are defined above;

R^{15} is selected from $\text{N}(\text{R}^{11})\text{NR}^{11a}\text{R}^{12}$, $\text{N}(\text{R}^{11})\text{OR}^{11a}$, $\text{NR}^{11}\text{C}(\text{R}^{11a}\text{R}^{11b})\text{COR}^{13}$, wherein R^{11} , R^{11a} , R^{11b} , R^{12} and R^{13} are defined above;

R^{16} is selected from group of the formula: $\text{R}-\text{R}^5$, $\text{CH}(\text{NH}_2)\text{CH}_2\text{OH}$ or CH ;

R^{17} is selected from SO_3H , $\text{SiR}^{11}\text{R}^{11a}\text{R}^{11b}$, $\text{SiOR}^{11}\text{OR}^{11a}\text{OR}^{11b}$, $\text{PR}^{11}\text{R}^{11a}$, $\text{P}(\text{O})\text{R}^{11}\text{R}^{11a}$,

$\text{P}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above;

R^{18} is selected from hydrogen and R^1 , wherein R^1 is defined above. Preferably R^{18} is CH_3 , $\text{CH}_2\text{CH}(\text{CH}_3)_2$, phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, phenyl-O-methylrhamnose-*p*;

for the preparation of a medicament for preventing infection of HIV, or treating infection by HIV or for treating AIDS or AIDS related complex.

Each compound of the present invention may be a pure stereoisomer coupled at each of its chiral centers or it may be inverted at one or more of its chiral centers. It may be a single stereoisomer or a mixture of two or more stereoisomers. If it is a mixture the ratio may or may not be equimolar. Preferably the compound is a single stereoisomer. Preferably the stereochemistry of the peptide core of the compound containing six amino acids (2-7) is 2(*R*), 3(*S*), 4(*R*), 5(*R*), 6(*S*) and 7(*S*).

The above mentioned compounds may be engineered to be less active or inactive antibacterials at therapeutically effective antiviral doses and it also has been demonstrated by this invention that they can be engineered to have no mammalian cell toxicity at therapeutically effective antiviral doses. Yet another preferred embodiment of present invention includes thus the use in a prophylactic treatment or therapeutic treatment or the use to manufacture a medicament to treat therapeutically or prophylactically a viral infection with vancomycin derivatives, eremomycin derivatives, eremomycin aglycon derivatives, Des-(N-methyl -D-leucyl)-eremomycin aglycon, DMDA40, DA40, DA40 derivatives, DMDA40 derivatives, teicoplanin aglycon derivatives, modified products of teicoplanin aglycon degradation or other structurally related

glycopeptide antibiotics. The compounds are selected for antiviral activity and low mammalian cell toxicity and eventually may be selected as additional property antibacterial inactivity in antiviral activity assays such as the anti-HIV assays of present invention, a cytostatic activity assay of the state of the art or the cytostatic activity assay on the mammalian cell lines (J.1210, 5 Molt4/C8 or CEM) of present invention and additional antibacterial assays of the state of the art.

Compounds of the present invention for use in a prophylactic treatment or therapeutic treatment or the use to manufacture a medicament to treat therapeutically or prophylactically a viral 10 infection, and preferably a retroviral infection and yet more preferably a HIV infection can be selected from the group of compounds 1 to 64 of the examples of this application.

DESCRIPTION

15 Definitions

As used herein, the term "halogen" refers to Cl, Br, I, F.

The term "alkyl" refers to straight or branched, substituted or unsubstituted, saturated or unsaturated C₁-C₂₄ hydrocarbon chains without or with suitable heteroatoms. The number and position of unsaturated bonds and heteroatoms may be varied. Any heteroatoms may be the 20 same or different and can, for example, be O, N, S or B. The nature, number and position of substituents may be varied. Any substituents may be the same or different and can, for example, be halogen, SH, OH, COOH, NO₂, NH₂, NHC(NH₂)=NH, CH(NH₂)=NH, NHOH, NHNH₂, N₃, NO, CN, N=NR¹¹, N=NR¹², SO₂R¹¹, SO₂R¹², B(OH)₂, B(OR¹¹)₂, CO, CHO, O-Sug, NR¹¹-Sug, R¹¹, R¹², R¹⁷ and R¹⁸, wherein R¹¹, R¹², R¹⁷ and R¹⁸ are described as above and Sug is any 25 cyclic or acyclic carbohydrate. Any substituents may themselves be substituted. The position, and number of any substituents may be varied.

The term "cycloalkyl", as used herein, refers to saturated or unsaturated, substituted or unsubstituted monocyclic, bicyclic, tricyclic and macrocyclic C₂-C₂₄ hydrocarbon chains. The 30 nature, number and position of substituents may be varied. Any substituents may be the same or different and can, for example, be halogen, SH, OH, COOH, NO₂, NH₂, NHC(NH₂)=NH, CH(NH₂)=NH, NHOH, NHNH₂, N₃, NO, CN, N=NR¹¹, N=NR¹², SO₂R¹¹, SO₂R¹², B(OH)₂, B(OR¹¹)₂, CO, CHO, O-Sug, NR¹¹-Sug, R¹¹, R¹², R¹⁷ and R¹⁸, wherein R¹¹, R¹², R¹⁷ and R¹⁸

are described as above and Sug is any cyclic or acyclic carbohydrate. Any substituents may themselves be substituted. The position, and number of any substituents may be varied. Typical cycloalkyls include cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclododecyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, adamantyl, bornyl, norbornyl and the like.

The term "heterocycloalkyl", as used herein, refers to saturated or unsaturated, substituted or unsubstituted monocyclic, bicyclic, tricyclic and macrocyclic C₂-C₂₄ hydrocarbon chains with suitable heteroatoms selected from S, O, N or B. The nature, number and position of substituents may be varied. Any substituents may be the same or different and can, for example, be halogen, SH, OH, COOH, NO₂, NH₂, NHC(NH₂)=NH, CH(NH₂)=NH, NHOH, NHNH₂, N₃, NO, CN, N=NR¹¹, N=NR¹², SOR¹¹, SO₂R¹¹, B(OH)₂, B(OR¹¹)₂, CO, CHO, O-Sug, NR¹¹-Sug, R¹¹, R¹², R¹⁷ and R¹⁸, wherein R¹¹, R¹², R¹⁷ and R¹⁸ are described as above and Sug is any cyclic or acyclic carbohydrate. Any substituents may themselves be substituted. The position, and number of any substituents may be varied. Typical heterocycloalkyls include piperazinyl, piperidiny, morpholinyl, quinuclidinyl, borabicyclononyl, crown ethers, azacrowns, thiocrowns and the like.

The term "aryl", as used herein, refers to a stable, saturated or unsaturated, substituted or unsubstituted, C₆ membered organic monocyclic ring; a stable, saturated or unsaturated, substituted or unsubstituted, C₇-C₁₀ membered organic fused bicyclic ring; a stable, saturated or unsaturated, substituted or unsubstituted, C₁₂-C₁₄ membered organic fused tricyclic ring; or a stable, saturated or unsaturated, substituted or unsubstituted, C₁₄-C₁₆ membered organic fused tetracyclic ring. Preferably the aryl is substituted by one or more moieties independently selected from the group comprising hydrogen, halogen, SH, OH, COOH, NO₂, NH₂, NHC(NH₂)=NH, CH(NH₂)=NH, NHOH, NHNH₂, N₃, NO, CN, N=NR¹¹, N=NR¹², SOR¹¹, SO₂R¹¹, B(OH)₂, B(OR¹¹)₂, CO, CHO, O-Sug, NR¹¹-Sug, R¹¹, R¹², R¹⁷ and R¹⁸, wherein R¹¹, R¹², R¹⁷ and R¹⁸ are described as above and Sug is any cyclic or acyclic carbohydrate. Any substituents may themselves be substituted. The position, and number of any substituents may be varied. Typical aryls include phenyl, biphenyl, triphenyl, naphthyl, fluorenyl, phenanthrenyl and the like.

The term "heteroaryl", as used herein, refers to a stable, saturated or unsaturated, substituted or unsubstituted, C₄-C₇ membered organic monocyclic ring having a heteroatom selected from S, O, and N; a stable, saturated or unsaturated, substituted or unsubstituted, C₉-C₁₀ membered organic fused bicyclic ring having one or more heteroatoms selected from S, O, and N; or a
5 stable, saturated or unsaturated, substituted or unsubstituted, C₁₂-C₁₄ membered organic fused tricyclic ring having one or more heteroatoms selected from S, O, and N. The nitrogen and sulfur atoms of these rings are optionally oxidized, and the nitrogen heteroatoms are optionally quarternized. Preferably the aryl is substituted by one or more moieties independently selected from the group comprising hydrogen, halogen, SH, OH, COOH, NO₂, NH₂, NHC(NH₂)=NH,
10 CH(NH₂)=NH, NHOH, NHNH₂, N₃, NO, CN, N=NR¹¹, N=NR¹², SOR¹¹, SO₂R¹¹, B(OH)₂, B(OR¹¹)₂, CO, CHO, O-Sug, NR¹¹-Sug, R¹¹, R¹², R¹⁷ and R¹⁸, wherein R¹¹, R¹², R¹⁷ and R¹⁸ are described as above and Sug is any cyclic or acyclic carbohydrate. Any substituents may themselves be substituted. The position, and number of any substituents may be varied. Typical heteroaryls include indolyl, quinolyl, piperidyl, thienyl, piperonyl, oxaflorenyl, pyridyl and
15 benzothienyl and the like.

The term "acyl", as used herein, refers to group of the formula: -COR¹¹, -COOR¹¹ or -CSR¹¹ wherein R¹¹ is described above.

20 The term "carbamoyl", as used herein, refers to group of the formula: -CONR¹¹R^{11a} or -CONHR¹² wherein R¹¹, R^{11a} and R¹² are described above.

The term "thiocarbamoyl" refers to group of the formula: -CSNHR¹² or -C⁺(SR¹¹)NHR¹², wherein R¹¹ and R¹² are described above.

25 The term "amino-protecting group" refers to those groups known in the art to be suitable for protecting the amino group during the acylation reaction. Such groups are well recognized, and selecting a suitable group for this purpose will be apparent. The tert-butoxycarbonyl (Boc), adamantyloxycarbonyl (Adoc), fluorenylmethoxycarbonyl (Fmoc) and carbobenzoxy carbonyl (Cbz) groups are examples of suitable amino-protecting groups.

30

The term "carbohydrate" refers to any cyclic or acyclic carbohydrate.

The term "glycopeptide antibiotics" refers to the natural glycopeptide antibiotics (glycopeptidic molecules produced by microorganisms such as actinomycetes with antibacterial activity) such as vancomycin, teicoplanin, eremomycin, DMDA40, DA40, their aglycon derivatives and various other structurally related glycopeptide antibiotics and semisynthetic derivatives.

Illustrative embodiments of the invention

The terminology used herein is not intended to limit the scope of the present invention but for the purpose of describing particular embodiments. This invention is not limited to the particular methodology, protocols and reagents described as these may vary.

The present invention includes a class of natural glycopeptide antibiotics and their derivatives and a class of compounds with structural similarity to said natural glycopeptide antibiotics which possess antiviral activity such as the anti-retroviral activity of presented examples. The invention also includes derivatives of glycopeptide antibiotics, which have been structurally engineered or modified to decrease or remove completely or partially the antibacterial activity while still comprising antiviral activity. The glycopeptide antibiotics are well known as powerful antibacterial agents against a wide variety of gram-positive bacteria and until now there is no data available about anti-viral, anti-retroviral or anti-HIV activity of such compounds. Several natural peptide antibiotics such as complestatins and chlorocephins with activity against HIV-1 (K. Matsuzara, H. et al J.Antibiotics 1994, V.47, N.10, p.1173-1174) and kistamycins with activity against influenza virus (N. Naruse, O, et al J. Antibiotics 1993, V.46, N.12, p.1812-1818) have been described. However the structures of these hexa- or heptapeptide antibiotics and the structures of glycopeptide antibiotics and of the aglycons of glycopeptide antibiotics have serious differences in both amino acid sequence and stereochemistry. All kystamycins, complestatin and chlorocephins contain a tryptophan moiety linked to central amino acid No 4, whereas it is represented by a substituted phenylalanine moiety in vancomycin, eremomycin, chloreremomycin, teicoplanin, DA-40926 and other antibacterial glycopeptides.


The present invention thus includes the use of selected compounds of the general formula I, II and III as an antiviral or to manufacture medicaments to treat or prevent antiviral infection, more preferably as a retroviral and more preferably as an anti-HIV and most preferably as an anti-HIV-1 or anti-HIV-2 compound. Such compounds can be natural glycopeptide antibiotics, with structures as for instance disclosed in K.C.Nicolaou, C.N.C. et al. Chem. Int. Ed., 1999, V.38, p.2096-2152 and B.Cavalleri & F.Parenti. Encyclopedia of Chemical Technology, 1992, V.2, p.995-1018.

The present invention, however, also provides synthetic, semisynthetic or biosynthetic derivatives of natural glycopeptide antibiotics of the general formula I, II and III. These compounds may be engineered to be inactive as antibacterials at therapeutic antiviral doses.


In a further preferred embodiment of present invention these antiviral compounds can be compounds of the formula I, II and III or salts thereof, wherein:

b^1 and b^2 each independently represents nihil or an additional bond, R^0 represents nihil when b^2 represents an additional bond and hydrogen when b^2 represents nihil, R^6 represents nihil when b^1 represents an additional bond and hydrogen when b^1 represents nihil, R^6 represents R^{6a} and R^0 represents hydrogen when b^1 and b^2 each represents nihil, wherein R^{6a} is described below. Preferably R^6 represents R^{6a} , R^0 represents hydrogen and b^1 and b^2 each represents nihil;


20 Formula I



Formula II



Formula III



5

b³ represents nihil or an additional bond, R^a---R^{5a} represents a group of the formula: CHN(R¹¹)CO, CHN(R¹¹)(CH₂)_zN(R^{11a})CO or CHN(R¹¹)CO(CH₂)_zN(R^{11a})CO when b³ represents an additional bond, and R^a is R and R^{5a} is R⁵ when b³ represents nihil, wherein z is 0, 1, 2, 3 or 4 and R, R⁵, R¹¹ and R^{11a} are described below. Preferably R^a---R^{5a} represents CHNHCO:

b^4 represents nihil or an additional bond, $R^b\text{---}R^{5b}$ represents a group of the formula:
 $\text{CHN}(R^{11})\text{CO}$, $\text{CHN}(R^{11})(\text{CH}_2)_z\text{N}(R^{11a})\text{CO}$ or $\text{CHN}(R^{11})\text{CO}(\text{CH}_2)_p\text{N}(R^{11a})\text{CO}$ when b^4
represents an additional bond, and R^b is R and R^{5b} is R^5 when b^4 represents nihil, wherein p is 0,
15 1, 2, 3 or 4 and R , R^5 , R^{11} and R^{11a} are described below;

b⁵, b⁶ and b⁷ each independently represents nihil or an additional bond. Y represents oxygen, R^d represents hydrogen and R represents R or a group of the formula: (CH₂)₆CON(R¹¹)CH(CH₂OH) (CH₂)₄N(R¹²)CH(CH₂OH) when b⁵ and b⁷ represent nihil and b⁶

represents an additional bond. R^{0a} represents nihil, R^d-Y represents a group of the formula: $CHN=C(NR^{11})O$ or $CHNHCON(R^{11})$ when b^6 represents nihil and b^5 represents an additional bond. Y and R^{0a} each represents a hydrogen and R^d represents group of the formula: $(CH_2)_qCON(R^{11})CH(CH_2OH)$ $(CH_2)_qN(R^{12})CH(CH_2OH)$ when b^5 , b^6 and b^7 each represents nihil, wherein q is 0, 1, 2, or 3 and R , R^{11} and R^{12} are described below;

n is 0, 1, 2 or 3;

X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen, halogen and X^6 , wherein X^6 is defined below. Preferably X^1 , X^2 , X^3 , X^4 , X^5 , X^7 and X^9 are each independently selected from hydrogen and Cl ;

- 10 X^6 is selected from the group comprising hydrogen, halogen, SO_3H , OH , NO , NO_2 , $NHNH_2$, $NHN=CHR^{11}$, $N=NR^{11}$, $CHR^{11}R^{13}$, $CH_2N(R^3)R^{11}$, R^5 , R^{11} and R^{13} , wherein R^3 is CH_2 attached to phenolic hydroxyl group of the 7th amino acid, R^5 , R^{11} and R^{13} are defined below. Preferably X^6 is CH_2R^{13} ;

X^8 is selected from hydrogen and methyl;

- 15 R^e represents R and R^{50} represents R^5 , wherein R and R^5 are defined below;

R is selected from CHR^{13} and R^{14} , wherein R^{13} and R^{14} are defined below. Preferably R is CHR^{13} ;

R^1 is selected from hydrogen and R^{11} , wherein R^{11} is defined below. Preferably R^1 is $(CH_2)_tCOOH$, $(CH_2)_tCONR^{11}R^{12}$, $(CH_2)_tCOR^{13}$, $(CH_2)_tCOOR^{11}$, COR^{15} , $(CH_2)_tOH$, $(CH_2)_tCN$,

- 20 $(CH_2)_tR^{13}$, $(CH_2)_tSCH_3$, $(CH_2)_tSOCH_3$, $(CH_2)_tS(O)_2CH_3$, $(CH_2)_tphenyl(m-OH, p-Cl)$, $(CH_2)_tphenyl(o-X^7, m-OR^{10}, p-X^8)-[O-phenyl(o-OR^9, m-X^9, m-R^{16})]-m$, where t is 0, 1, 2, 3 or 4. R , X^7 , X^8 , X^9 are defined above. R^{11} , R^{12} , R^{13} , R^{15} and R^{16} are defined below;

R^2 and R^4 are each independently selected from hydrogen, R^{12} and R^{17} , wherein R^{12} and R^{17} are defined below;

- 25 R^3 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or O-acetylmannosyl. R^{12} and R^{17} are defined below; R^5 is selected from $COOH$, $COOR^{11}$, COR^{13} , COR^{15} , CH_2OH , $CH_2halogen$, CH_2R^{13} , CHO , $CH=NOR^{11}$, $CH=NNR^{11}R^{12}$ and $C=NNHCONR^{11}R^{12}$, wherein R^{11} , R^{12} , R^{13} and R^{15} are defined below;

- 30 R^{6a} is selected from OR^{12} , OR^{17} , OH , O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, ristosaminy, N-acetylglucosaminy, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, glucuronyl, 4-oxovancosaminy, ureido-4-oxovancosaminy and their derivatives with functional groups such

as, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $\text{NR}^{11}\text{R}^{12}$, $\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, COOR^{11} , COR^{13} , COR^{15} , O-R^{12} , O-R^{17} , C=NOR^{11} , CHNHOR^{11} , $\text{C=NNR}^{11}\text{R}^{12}$ and $\text{C=NNHCONR}^{11}\text{R}^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

- 5 R^7 is selected from hydrogen, R^{12} , R^{17} , Sug and alkyl-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is glucosyl, mannosyl, ristosaminy, N-acylglucosaminy, N-acylglucuronyl, glucosaminy, glucuronyl, 4-*epi*-vancosaminy, 3-*epi*-vancosaminy, vancosaminy, actinosaminy, acosaminy, glucosyl-vancosaminy, glucosyl-4-*epi*-vancosaminy, glucosyl-3-*epi*-vancosaminy, glucosyl-acosaminy, glucosyl-ristosaminy, 10 glucosyl-actinosaminy, glucosyl-rhamnosyl, glucosyl-olivoyl, glucosyl-mannosyl, glucosyl-4-oxovancosaminy, glucosyl-ureido-4-oxovancosaminy, glucosyl(rhamnosyl)-mannosyl-arabiny, glucosyl-2-O-Leu and their derivatives with as functional groups, for example, amino, carboxy, hydroxy and oxo. Typical carbohydrate derivatives comprising $\text{NR}^{11}\text{R}^{12}$, $\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, COOR^{11} , COR^{13} , COR^{15} , O-R^{12} , O-R^{17} , C=NOR^{11} , CHNHOR^{11} , $\text{C=NNR}^{11}\text{R}^{12}$ and $\text{C=NNHCONR}^{11}\text{R}^{12}$ derivatives, wherein R^{11} , R^{11a} , R^{11b} , R^{12} , R^{13} , R^{15} and R^{17} are defined below;

R^8 is selected from hydrogen, R^{12} , R^{17} , OH, O-alkyl-Sug and O-Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is O-mannosyl, O-galactosyl and O-galactosyl-galactosyl;

- 20 R^9 is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is galactosyl or galactosyl-galactosyl. R^{12} and R^{17} are defined below;

R^{10} is selected from hydrogen, R^{12} , R^{17} or Sug, wherein Sug is any cyclic or acyclic carbohydrate. Preferably Sug is mannosyl or fucosyl. R^{12} and R^{17} are defined below;

- 25 R^{11} , R^{11a} and R^{11b} are each independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cyloalkyl, heterocycloalkyl;

R^{12} and R^{12a} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, acyl, amino-protecting group, carbamoyl, thiocarbamoyl, SO_2R^{11} , S(O)R^{11} , $\text{COR}^{13}\text{-R}^{18}$, $\text{COCHR}^{18}\text{N(NO)R}^{11}$, $\text{COCHR}^{18}\text{NR}^{11}\text{R}^{12}$ and 30 $\text{COCHR}^{18}\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above, R^{13} and R^{18} are defined below. Preferably R^{12a} is hydrogen, $\text{COCHR}^{18}\text{NR}^{11}\text{R}^{12}$, $\text{COCHR}^{18}\text{N(NO)R}^{11}$, $\text{COCHR}^{18}\text{N}^+\text{R}^{11}\text{R}^{11a}\text{R}^{11b}$ and $\text{COCHR}^{18}\text{R}^{13}$;

R^{13} is selected from the group consisting of hydrogen, NHR^{12a} , $NR^{11}R^{12}$, $NR^{11}Sug$, $N^+R^{11}R^{11a}R^{11b}$, R^{15} , $NR^{11}C(R^{11a}R^{11b})COR^{13}$ and group of the formula:

$N-A-N^+-A$

wherein A is $-CH_2-B-CH_2-$ and B is $-(CH_2)_m-D-(CH_2)_r-$, wherein m and r are from 1 to 4 and D is O, S, NR^{12} , $N^+R^{11}R^{11a}$, wherein Sug is any cyclic or acyclic carbohydrate, R^{11} , R^{11a} and R^{12} are defined above;

R^{14} is CH_2 , $C=O$, $CHOH$, $C=NOR^{11}$, $CHNHOR^{11}$, $C=NNR^{11}R^{12}$, $C=NNHCONR^{11}R^{12}$ and $CHNHNR^{11}R^{12}$, wherein R^{11} and R^{12} are defined above;

R^{15} is selected from $N(R^{11})NR^{11a}R^{12}$, $N(R^{11})OR^{11a}$, $NR^{11}C(R^{11a}R^{11b})COR^{13}$, wherein R^{11} , R^{11a} , R^{11b} , R^{12} and R^{13} are defined above;

R^{16} is selected from group of the formula: $R-R^5$ or $CH(NH_2)CH_2OH$;

R^{17} is selected from SO_3H , $SiR^{11}R^{11a}R^{11b}$, $SiOR^{11}OR^{11a}OR^{11b}$, $PR^{11}R^{11a}$, $P(O)R^{11}R^{11a}$, $P^+R^{11}R^{11a}R^{11b}$, wherein R^{11} , R^{11a} and R^{11b} are defined above;

R^{18} is selected from hydrogen and R^1 , wherein R^1 is defined above. Preferably R^{18} is CH_3 , $CH_2CH(CH_3)_2$, phenyl(*p*-OH, *m*-Cl), phenyl-rhamnose-*p*, phenyl-(rhamnose-galactose)-*p*, phenyl-(galactose-galactose)-*p*, phenyl-O-methylrhamnose-*p*;

Each compound of the present invention may be a pure stereoisomer coupled at each of its chiral centers or it may be inverted at one or more of its chiral centers. It may be a single stereoisomer or a mixture of two or more stereoisomers. If it is a mixture, the ratio may or may not be equimolar. Preferably the compound is a single stereoisomer. Preferably the stereochemistry of the peptide core of the compound containing six amino acids (2-7) is 2(*R*), 3(*S*), 4(*R*), 5(*R*), 6(*S*) and 7(*S*).

Yet another embodiment of present invention is the use of one or more compounds of the formulas I, II or III in a pharmaceutical composition to treat or prevent a viral infection, preferably retroviral infection and yet more preferably a HIV-1 or HIV-2 infection. Thus, one or more of the compounds, preferably in the form of a pharmaceutically acceptable salt, can be formulated for oral or parenteral or topical administration for therapeutic or prophylactic treatment a viral infection, preferably of retroviral infection and yet more preferably of HIV infections.


For example: the compound can be mixed with pharmaceutically acceptable carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, gels, syrups, wafers

and the like. The compositions comprising one or more compounds of the general formula I, II or III or derivatives of these compound will contain from about 0.01 to about 90 % by weight of the active compound, and more preferably from about 10 to about 30 %. The composition may contain pharmaceutical acceptable carriers and excipients, such as corn starch, or gelatin, 5 lactose, sucrose, microcrystalline cellulose, dicalcium phosphate, sodium rilloride, and alginic acid.

For intravenous use, a water soluble form of the compounds of present invention can be dissolved in one of the commonly used intravenous fluids or any pharmaceutically acceptable 10 fluid for intravenous injection and administered by infusion. Such fluids as, for example, physiological saline, Ringer's solution, or % dextrose solution can be used. For intramuscular preparation, a sterile formulation of a suitable soluble salt form of the compound, for example a hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as pyrogen-free water (distilled), physiological saline or 5 % glucose solution. A suitable insoluble 15 form of the compound may be prepared and administered as a suspension in an adequate base or a pharmacologically acceptable oil base, for example, an ester of a long chain fatty acid such as ethyl oleate. For topical (i.e. intravaginal) use, a sterile formulation of a suitable form of the compound can be incorporated in a gel or a cream or alike.


Examples

5

Examples**Scheme 1. Vancomycin and eremomycin derivatives**

Code no.	X	Y	Z	Brutto formula	MW Calc.
Vancomycin derivatives W=Cl, S₁=Glu, S₂=vancosamine, S₃=H					
1	CH ₂ N[CH ₂ CH ₂] ₂ NBnBu-p	OH	H	C ₈₂ H ₉₉ N ₁₁ O ₂₄ Cl ₂	1694
2	H	NH(CH ₂) ₃ N ⁺ Me ₂ C ₁₀ H ₂₁	H	C ₈₁ H ₁₀₃ N ₁₁ O ₂₃ Cl ₂	1673
Eremomycin derivatives W=H, S₁=Glu, S₂=S₃=eremosamine					
3	CH ₂ NHBnBu-p	NHMe	H	C ₈₆ H ₁₀₈ N ₁₂ O ₂₅ Cl	1727
4	CH ₂ NH(CH ₂) ₃ N ⁺ Me ₂ C ₁₀ H ₂₁	NH(CH ₂) ₃ NMe ₂	H	C ₉₄ H ₁₃₆ N ₁₄ O ₂₅ Cl	1895
5	CH ₂ N[CH ₂ CH ₂] ₂ NBnBu-p	NHMe	H	C ₉₀ H ₁₁₆ N ₁₃ O ₂₅ Cl	1813
Eremomycin aglycon derivatives W=S₁=S₂=S₃=H					
6	CH ₂ N[CH ₂ CH ₂] ₂ NBnPh-p	OH	H	C ₇₁ H ₇₉ N ₁₀ O ₁₇ Cl	1374

7	$\text{CH}_2\text{N}[\text{CH}_2\text{CH}_2]_2\text{NB}$ nPh-p	NHMe	Boc	$\text{C}_{77}\text{H}_{86}\text{N}_{11}\text{O}_{18}\text{Cl}$	1487
8	$\text{CH}_2\text{N}[\text{CH}_2\text{CH}_2]_2\text{NB}$ nPh-p	NHMe	H	$\text{C}_{72}\text{H}_{78}\text{N}_{11}\text{O}_{16}\text{Cl}$	1387
9	H	$\text{NHCH}_2(\text{Adam-1})$	H	$\text{C}_{64}\text{H}_{70}\text{N}_9\text{O}_{16}\text{Cl}$	1255
10	H	NHBn-F-p	H	$\text{C}_{60}\text{H}_{59}\text{N}_9\text{O}_{16}\text{FCl}$	1215
11	H	perhydroiso-quinol- 1-yl	H	$\text{C}_{62}\text{H}_{65}\text{N}_9\text{O}_{16}\text{Cl}$	1229
12	H	$\text{N}(\text{C}_6\text{H}_{11})\text{CONH-}$ C_6H_{11}	H	$\text{C}_{66}\text{H}_{75}\text{N}_{10}\text{O}_{17}\text{Cl}$	1314




Code no.	X	Y	Z	Brutto formula	MW Calc.
Des-(N-methyl-D-leucyl)-eremomycin aglycon (hexapeptide) $\text{W}=\text{S}_1=\text{S}_2=\text{S}_3=\text{H}$					
13	CH_2NHAdam	NHMe	H	$\text{C}_{58}\text{H}_{50}\text{N}_8\text{O}_{15}\text{Cl}$	1143
14	H	H	D-Trp	$\text{C}_{57}\text{H}_{50}\text{N}_9\text{O}_{17}\text{Cl}$	1167

5

10

15


Scheme 2. N-deacyl-A40926 (DA40), demannosyl-N-deacylA40926 (DMDA40) and their derivatives.



Code no.	X	Y ¹ =Y ²	Z ¹	Z ²	Brutto formula	MW
DMDA40						
15	H	NH(CH ₂) ₆ N ⁺ Me ₂ BnPh-p	H	H	C ₁₀₇ H ₁₁₂ N ₁₂ O ₂₆ Cl ₂	2053
16	H	NH(CH ₂) ₃ N Me ₂	p-BuOBn	p-BuOBn	C ₉₇ H ₁₀₆ N ₁₂ O ₂₅ Cl ₂	1881

17	H	NH(CH ₂) ₃ N Me ₂	H	p-BuBn	C ₈₆ H ₉₄ N ₁₂ O ₂₁ Cl ₂	1703
18	CH ₂ N[CH ₂ CH ₂] ₂ N BuPh-p	NH(CH ₂) ₃ N Me ₂	H	p-BuBn	C ₁₀₄ H ₁₁₄ N ₁₄ O ₂₁ Cl ₂	1967
19	CH ₂ NH(CH ₂) ₃ N ⁺ Me ₂ C ₁₀ H ₁₂₁	NH(CH ₂) ₃ N Me ₂	H	H	C ₉₁ H ₁₁₅ N ₁₄ O ₂₁ Cl ₂	1812

Scheme 3. Teicoplanin aglycon derivatives.




5

Code no.	X	Y	Z	Brutto formula	MW
Teicoplanin aglycon (TD) derivatives					
20	CH ₂ NHC ₁₀ H ₂₁	NH(CH ₂) ₃ NMe ₂	H	C ₇₄ H ₈₀ N ₁₀ O ₁₇ Cl ₂	1452
21	CH ₂ NH(CH ₂) ₄ CH(NH ₂) CONHC ₁₀ H ₂₁	NH(CH ₂) ₃ NMe ₂	H	C ₈₀ H ₉₂ N ₁₂ O ₁₈ Cl ₂	1580
22	CH ₂ N[CH ₂ CH ₂] ₂ NN= CHPhCl-p	OH	H	C ₇₀ H ₅₉ N ₁₀ O ₁₈ Cl ₃	1434
23	CH ₂ N(COLys)C ₁₀ H ₂₁	NH(CH ₂) ₃ NMe ₂	H	C ₇₂ H ₇₃ N ₉ O ₁₇ Cl ₂	1407
24	CH ₂ NHAdam	NH(CH ₂) ₃ NMe ₂	H	C ₇₄ H ₇₄ N ₁₀ O ₁₇ Cl ₂	1446
25	CH ₂ NH(CH ₂) ₃ NMe ₂	NHC ₁₀ H ₂₁	H	C ₇₄ H ₈₀ N ₁₀ O ₁₇ Cl ₂	1452
26	CH ₂ NHC ₉ H ₁₉	NH(CH ₂) ₃ NMe ₂	H	C ₇₃ H ₇₈ N ₁₀ O ₁₇ Cl ₂	1436
27	CH ₂ NHC ₁₀ H ₂₁	NH(CH ₂) ₃ -2-Me- pipercoline	H	C ₇₈ H ₈₆ N ₁₀ O ₁₇ Cl ₂	1497
28	H	NH(CH ₂) ₄ CH(NH ₂)CO NHC ₁₀ H ₂₁	H	C ₇₄ H ₇₈ N ₁₀ O ₁₈ Cl ₂	1466

29	$\text{CH}_2\text{NHC}_{10}\text{H}_{21}$	NHMe	COLys	$\text{C}_{76}\text{H}_{89}\text{N}_{11}\text{O}_{18}\text{Cl}_2$	1509
30	H	$\text{N}[(\text{CH}_2\text{CH}_2)_2\text{N}-2\text{-naphthyl}]$	H	$\text{C}_{73}\text{H}_{61}\text{N}_9\text{O}_{17}\text{Cl}_2$	1407
31	H	$\text{NH}(\text{CH}_2)_4\text{CH}(\text{NHBnOBu-p})\text{CONH}(\text{CH}_2)_3\text{NMe}_2$	H	$\text{C}_{86}\text{H}_{88}\text{N}_{11}\text{O}_{19}\text{Cl}_2$	1636
32	H	$\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	H	$\text{C}_{73}\text{H}_{78}\text{N}_9\text{O}_{17}\text{Cl}_2$	1424
33	$\text{CH}_2\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NBnPh-p}]$	$\text{NH}(\text{CH}_2)_3\text{NMe}_2$	H	$\text{C}_{81}\text{H}_{77}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1547
34	$\text{CH}_2\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NBnPh-p}]$	$\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_3$	H	$\text{C}_{82}\text{H}_{80}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1562
35	$\text{CH}_2\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NBnBu-p}]$	$\text{NH}(\text{CH}_2)_3\text{NMe}_2$	H	$\text{C}_{79}\text{H}_{81}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1527
36	$\text{CH}_2\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NBnBu-p}]$	NHMe	H	$\text{C}_{75}\text{H}_{72}\text{N}_{10}\text{O}_{17}\text{Cl}_2$	1456
37	H	$\text{NH}(\text{CH}_2)_3\text{NMe}_2$	$\text{C}_{11}\text{H}_{23}$	$\text{C}_{74}\text{H}_{79}\text{N}_9\text{O}_{17}\text{Cl}_2$	1437
38	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	OH	H	$\text{C}_{74}\text{H}_{80}\text{N}_9\text{O}_{18}\text{Cl}_2$	1454
39	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	$\text{NH}(\text{CH}_2)_3\text{NMe}_2$	H	$\text{C}_{79}\text{H}_{92}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1538
40	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	NHMe	H	$\text{C}_{75}\text{H}_{83}\text{N}_{10}\text{O}_{17}\text{Cl}_2$	1467
41	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	$\text{NH}(\text{CH}_2)_2\text{OH}$	H	$\text{C}_{76}\text{H}_{85}\text{N}_{10}\text{O}_{18}\text{Cl}_2$	1497
42	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	$\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	H	$\text{C}_{89}\text{H}_{113}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1679
43	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	$\text{NH}(\text{CH}_2)_3\text{NMe}_2$	H	$\text{C}_{79}\text{H}_{90}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1536
44	$\text{CH}_2\text{N}[(\text{CH}_2\text{CH}_2)_2\text{N}^+\text{C}_{10}\text{H}_{21}]$	$\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	H	$\text{C}_{89}\text{H}_{111}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1677
45	H	$\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NCO}]\text{C}_9\text{H}_{19}$	H	$\text{C}_{72}\text{H}_{71}\text{N}_9\text{O}_{18}\text{Cl}_2$	1448
46	H	$\text{NH}(\text{CH}_2)_6\text{NH}_2$	H	$\text{C}_{84}\text{H}_{59}\text{N}_9\text{O}_{17}\text{Cl}_2$	1297
47	$\text{CH}_2\text{NH}(\text{CH}_2)_3\text{N}^+\text{Me}_2\text{C}_{10}\text{H}_{21}$	$\text{NH}(\text{CH}_2)_6\text{NH}_2$	H	$\text{C}_{80}\text{H}_{94}\text{N}_{11}\text{O}_{17}\text{Cl}_2$	1552
48	H	$\text{NH}(\text{CH}_2)_{10}\text{NH}_2$	H	$\text{C}_{68}\text{H}_{67}\text{N}_9\text{O}_{17}\text{Cl}_2$	1353
49	H	$\text{NH}(\text{CH}_2)_5\text{CO-D-Ala-D-Ala}$	Boc	$\text{C}_{75}\text{H}_{74}\text{N}_{10}\text{O}_{23}\text{Cl}_2$	1554
50	CH_2NHMe	NHMe	H	$\text{C}_{61}\text{H}_{53}\text{N}_9\text{O}_{17}\text{Cl}_2$	1255
51	H	$\text{N}[(\text{CH}_2\text{CH}_2)_2\text{NCOCH}_2\text{NHBnBu-p}]$	H	$\text{C}_{75}\text{H}_{70}\text{N}_{10}\text{O}_{18}\text{Cl}_2$	1470
52	$\text{CH}_2\text{NHBnBu-p}$	NHMe	Boc	$\text{C}_{76}\text{H}_{73}\text{N}_9\text{O}_{19}\text{Cl}_2$	1487
53	$\text{CH}_2\text{NHBnBu-p}$	NHMe	H	$\text{C}_{71}\text{H}_{65}\text{N}_9\text{O}_{17}\text{Cl}_2$	1387
54	H	OH	Adoc	$\text{C}_{69}\text{H}_{59}\text{N}_7\text{O}_{20}\text{Cl}_2$	1377
55	H	NHAdam	H	$\text{C}_{68}\text{H}_{60}\text{N}_8\text{O}_{17}\text{Cl}_2$	1332
56	CH_2NHAdam	NHMe	H	$\text{C}_{70}\text{H}_{63}\text{N}_9\text{O}_{17}\text{Cl}_2$	1375


57	CH ₂ NHAdam	NHAdam	H	C ₇₅ H ₇₇ N ₉ O ₁₇ Cl ₂	1495
58	H	N(CH ₃)CH(Adam-1)	H	C ₇₀ H ₆₄ N ₈ O ₁₇ Cl ₂	1359
59	H	NHBu-F-p	H	C ₆₅ H ₅₁ N ₈ O ₁₇ FC1 ₂	1304
60	H	NHCH ₂ (Adam-1)	H	C ₆₉ H ₆₂ N ₈ O ₁₇ Cl ₂	1344
61	H	N(C ₆ H ₁₁)CONHC ₆ H ₁₁	H	C ₇₁ H ₆₇ N ₉ O ₁₈ Cl ₂	1403



Scheme 4. Modified products of teicoplanin aglycon degradation

Compound 62. X = CH₂NHAdam, Y = Boc; C₆₇H₆₈N₆O₁₈Cl₂, 1315

Compound 63. X = CH₂NHAdam, Y = H; C₆₂H₆₀N₆O₁₆Cl₂, 1215



Compound 64. X = CH₂NHAdam, C₇₀H₆₈N₉O₁₃Cl₂S, 1498

5 Footnote: Adam = adamant-1-yl.

METHODS OF SYNTHESIS

Method A. Aminomethylated derivatives(1, 6, 62, 63, 64)

To a stirred solution of 0.5 mmol of antibiotic or its degradation product and 4 mmol of an appropriate amine in 10 ml of an acetonitrile-water 1 : 1 mixture was added 3 mmol of 37% aqueous formaldehyde. If a salt of amine was used 1n NaOH was added to pH 10. The reaction mixture was stirred at room temperature for 18 h and then 100 ml of water was added. After adjusting the reaction mixture at pH 3 with 1n HCl, the resulting solution (or suspension) was extracted with *n*-BuOH (~ 25 ml x 2); the organic layer was washed with water (~ 15 ml x 2) and then concentrated at 45 °C in a vacuum to a small volume (~3 ml). On adding ether (~ 100 ml), the precipitated solid was collected and dried in vacuum at room temperature for 4 h. Then it was dissolved in a minimal amount of MeOH and applied to a chromatographic column with Sephadex LH-20 (2 x 100 cm) preequilibrated with MeOH. The column was developed with MeOH at a rate of 10 ml/h, while collecting 5 ml fractions. The suitable fractions were combined and concentrated to a small volume (~ 3 ml). After adding ether (~ 100 ml) the precipitate formed was collected, rinsed with ether and dried in vacuum at room temperature.

The starting compound for 62 – N²-Cbz-N⁴-Boc-TDTP-Me – was obtained as previously described¹. Compound 63 was obtained from 62 by the removal of Boc-group in TFA as previously described for N³-Cbz-N⁴-Boc-TDTP-Me¹.

1. Malabarba, A.; Ciabatti, R.; Maggini, M.; Ferrari, P.; Vekey, K.; Colombo, L.; Denaro, M. Structural modifications of the active site in teicoplanin and related glycopeptides. 2. Deglycoteicoplanin-derived tetrapeptide. *J. Org. Chem.* 1996, 61, 2151–2157.

The starting compound for 64 – N-terminal phenylthiohydantoin-derivative of teicoplanin aglycon – was obtained by Edman degradation of teicoplanin aglycon.

Method B. Carboxamides (2, 9, 10, 11, 12, 15, 28, 30, 31, 32, 34, 45, 46, 48, 51, 55, 58, 59, 60, 61)

To a mixture of an antibiotic or its degradation product (0.5 mmol) and 5 mmol of an amine hydrochloride dissolved in 5 ml of DMSO were added portion-wise Et₃N to adjust pH 8.5-9 and afterwards during 1 hour 1 mmol of PyBOP - reagent (benzotriazol-1-yloxy)-tris-(pyrrolidino) phosphonium-hexafluorophosphate) or HBPYU-reagent (O-(benzotriazol-1-

xyloxy)-N,N,N',N'-bis(tetramethylene)uronium hexafluorophosphate). The reaction mixture was stirred at room temperature for 3 hours.

Addition of ether (~100 ml) to the reaction mixture led to an oily residue, which was shaken successively with ether (15 ml x 2) and acetone (~15 ml). After addition of 100 ml of acetone a

- 5 precipitate of crude amide was collected, dissolved in 50 ml of water and 1*n* NaOH was added to pH 9. The resulting solution (or suspension) was extracted with *n*-BuOH (~ 25 ml x 3); the organic layer was washed with water (~ 15 ml x 3) and then concentrated at 45 °C in vacuum to a small volume (~3 ml). On adding ether (~ 100 ml), the precipitated solid was collected and dried in a vacuum at room for 4 h. and 100 ml of acetone was added to form the precipitate, 10 which was collected to give a pure carboxamide.

Method C. Carboxamides of aminomethylated derivatives (3, 4, 5, 8, 13, 19, 20, 216, 22, 23, 24, 25, 26, 27, 33, 35, 36, 39, 40, 41, 42, 43, 44, 47, 50, 53, 56, 57)

- These compounds were obtained by the method B starting from the aminomethylated derivatives 15 obtained by the method A.

Method D. N-carbamoylated derivative. (54)

- To a stirred solution of 0.5 mmol of antibiotic or its degradation product in 15 ml THF-water 1 : 1 mixture adjusted to pH 10 with 1*n* NaOH 0.55 mmol of adamantyloxycarbonyl chloride was added. The reaction mixture was stirred at room temperature for 4 h, then it was diluted with 20 100 ml of water. After adjusting the reaction mixture at pH 3 with 1*n* HCl, the resulting solution (or suspension) was extracted with *n*-BuOH (~ 25 ml x 2); the organic layer was washed with water (~ 15 ml x 2) and then concentrated at 45 °C in vacuum to a small volume (~3 ml). On adding ether (~ 100 ml), the precipitated solid was collected and dried in vacuum at room temperature for 4 h.

- 25 **Method E. N-(D-Trp)-(de-N-Me-D-Leu)eremomycin aglycon 14**

Compound 14 was obtained previously described.²

2. Miroshnikova, O.V.; Berdnikova, T.F.; Olsufyeva, E.N.; Pavlov, A.Y.; Reznikova, M.I.; Preobrazhenskaya, M.N.; Ciabatti, R.; Malabarba, A.; Colombo, L. A Modification of the *N*-Terminal Amino Acid in the Eremomycin Aglycone. *J. Antibiot.* 1996, 49, 1157-1161.

- 30 **Method F. N-carbamoylated derivative of carboxamide (49)**

This compound was obtained by the method D using Boc_2O reagent starting from carboxamide obtained by the method B.

Method G. N-carbamoylated derivative of carboxamides of aminomethylated derivatives (7, 29, 52)

- 5 These compounds were obtained by the method D using Boc_2O reagent starting from carboxamides of aminomethylated derivatives obtained by the method C.

Method H. N- or N,N'-alkylated derivatives (16, 17, 18, 37)

- 10 To a stirred solution of 0.5 mmol of the starting compound [ethylaminopiperazinamide of DMDA 40, obtained by the method B for compound 17; 7d-methyl-N(p-phenylbenzyl)piperazine of di-ethylaminopropylamide of DMDA40 for compound 18; 7d-methylaminobutyl-N(nonyldimethyl)-amine of di-dimethylaminopropylamide of teicoplanin aglycone obtained by the method C for compound 37], 1.5 mmol of the corresponding aldehyde was added and the reaction mixture was stirred at 40 °C for 3 h. Then the reaction mixture was
- 15 cooled to 20 °C and 1 mmol of NaCNBH_3 was added. After stirring at 20 °C for 1 h 150 ml of ether was added to the reaction mixture to give an oily residue, which was shaken successively with ether (15 ml x 2) and acetone (~15 ml). After addition of 100 ml of acetone, a precipitate of crude amide was collected, dissolved in 50 ml of water and 1N NaOH was added to pH 9. The resulting solution (or suspension) was extracted with *n*-BuOH (~25 ml x 3); the organic
- 20 layer was washed with water (~15 ml x 3) and then concentrated at 45 °C in vacuum to a small volume (~3 ml). On adding ether (~100 ml), the precipitated solid was collected and dried in vacuum at room for 4 h. and 100 ml of acetone was added to form the precipitate, which was collected to give a pure product.

- 25 Changing the nature of the sugar residues of the glycopeptide antibiotics such as vancomycin can be performed as described in Nicas, T.I. et al. (Antimicrobial agents and Chemotherapy, 1996, 40, 2194-2199.)

- 30 Degradation products, the aglycon antibiotics can be obtained through chemical degradation as described as examples hereunder.

Eremomycin aglycon was obtained as described in Berdnikova, T.F. et al (Berdnikova, T.F.; Lomakina, N.N.; Olsufyeva, E.N.; Alexandrova, L.G.; Potapova, N.P.; Rozinov, B.V.; Malkova, I.V.; Orlova, G.I. Structure and Antimicrobial Activity of Products of Partial Degradation of Antibiotic Eremomycin. Antibiotics and Chemotherapy (Rus) 1991, 36, 28–31).

- 5 1000 mg (0.6 mmol) of eremomycin sulfate were dissolved in 20 ml of HCl (concentrated) and were kept at a room temperature for 5 h. Then 60 ml of water were added to precipitate eremomycin aglycon. The mixture was cooled to 5 °C and kept in refrigerator for 3 h. The solid was filtered off, washed with 10 ml of cool water, then with acetone and dried in vacuum. The solid was dissolved in 6 ml of DMSO and was added to 60 ml of acetone. The precipitate was
10 filtered off, washed with acetone and dried to yield 530 mg of a crude eremomycin aglycon. The water filtrate was passed through column (2x10 cm) of Dowex 50x2 resin (H⁺-form), which was washed with water and eluted with 50 ml of 0.25 N NH₄OH. The eluates were concentrated in vacuum with n-BuOH to minimal volume and precipitated with 50 ml acetone. The precipitate was collected, washed with acetone and dried in vacuum to give a crude
15 eremomycin aglycon. The samples were analyzed by TLC on the Merck Silica Gel 60F₂₅₄ plates in systems EtOAc-PrOH-25% NH₄OH 2:2:3 with UV control.

- The solids were combined and dissolved in 10 ml of 0.05 M AcONH₄-EtOH 9:1 mixture while acidified with 2 N HCl to pH 3 and applied to a chromatographic column with CM 32 carboxymethyl cellulose (Whatman, Great Britane) (45 cm x 2 cm) preequilibrated with 0.05
20 M AcONH₄-EtOH 9:1 mixture (pH 6.7). The column chromatography was carried out with 0.05 M AcONH₄-EtOH 9:1 mixture (pH 6.7) (300 ml), 0.1 M AcONH₄-EtOH 9:1 mixture (pH 6.7) (700 ml), then 0.15 M AcONH₄-EtOH 9:1 mixture (pH 6.7) (700 ml) at a flow rate 30 ml/h. The fractions containing eremomycin aglycon were combined, acidified with 6 N HCl to pH 3 and passed through column (2x10 cm) of Dowex 50x2 resin (H⁺-form), which was washed with
25 water and eluted with 50 ml of 0.25 N NH₄OH. The eluates were concentrated in vacuum with n-BuOH to minimal volume, acidified with 0.05 N HCl to pH 5 and precipitated with 50 ml acetone. The precipitate was collected, washed with acetone and dried in vacuum to give 310 mg (0.28mmol) oferemomycin aglycon (46.7 %).

- 30 Des-(N-methyl-D-leucyl) eremomycin aglycon was obtained from eremomycin aglycon as described in Miroshnikova, O.V. et al. (Miroshnikova, O.V.; Berdnikova, T.F.; Olsufyeva, E.N.; Pavlov, A.Y.; Reznikova, M.I.; Preobrazhenskaya, M.N.; Ciabatti, R.; Malabarba, A;

Colombo, L. A Modification of the N-Terminal Amino Acid in the Eremomycin Aglycone. J. Antibiot. 1996, 49, 1157-1161.

Teicoplanin aglycon was obtained as described in Malabarba, A. et al. (Malabarba, A.; Ferrari, P.; Gallo, G.G.; Kettenring, J.; Cavalleri, B. Teicoplanin, Antibiotics from *Actinoplanes teichomyceticus* nov. sp. VII. Preparation and NMR Characteristics of the Aglycone of Teicoplanin. J. Antibiotics 1986, 39, 1430-1442). The starting compound N-terminal phenylthiohydantoin-derivative of teicoplanin aglycon, was obtained by Edman degradation of teicoplanin aglycon. To a solution of teicoplanin aglycon (100mg, ~0.08 mmol) in a mixture of Py/H₂O (6:1, 4 mL), triethyl amine (0.26 mL, 2 mmol) and PhNCS (0.02 mL, ~0.16 mmol) were added at room temperature under argon. The reaction mixture was stirred for 16 h, then 8 mL of H₂O were added and the reaction mixture was evaporated with n-BuOH to dryness. The precipitate was dissolved in the mixture of TFA-CH₂Cl₂, 1:1 (3 mL) at 0-5 °C and then was stirred at this temperature for 1h. Water (3 mL) was then added and the mixture was neutralized with 25 % NH₄OH, washed with EtOAc (3 mL x 3), and the aqueous fraction was concentrated in vacuum with the addition of n-BuOH and applied to a column of silanized silica gel (2 x 100 cm), previously equilibrated with 0.01M acetic acid. The column was eluted with acetic acid (0.01M) at a flow rate of 30 mL/h for elution of compound N-terminal phenylthiohydantoin-derivative of teicoplanin aglycon. Fractions were pooled, concentrated with the addition of n-BuOH in vacuum, and acetone (50 mL) was added to yield the precipitate, which was filtered off, washed with acetone and dried to yield 68 mg (54 %).

The homogeneity and identity of the compounds obtained was assessed by HPLC and ESI mass-spectrometry. Analytical reverse phase HPLC was carried out on a Shimadzu HPLC instrument of the LC 10 series on a Diasorb C16 column (particle size 7 µm) at an injection volume of 10 µL and a wavelength 280 nm. The sample concentration was 0.05-0.2 mg/mL. Mass spectra were determined by Electrospray Ionisation (ESI) on a Finnigan SSQ7000 single quadrupole mass spectrometer.

ANTIVIRAL AND CYTOSTATIC ASSAY METHODS

Anti-HIV activity assays

Inhibition of HIV-1(III_B, HE, HN) and HIV-2(ROD, EHO, RF)-induced cytopathicity in CEM or C8166 or Molt4/C8 cells was measured in microtiter 96-well plates containing $\sim 3 \times 10^5$ CEM cells/ml, infected with 100 CCID₅₀ of HIV per ml and containing appropriate dilutions of the test compounds. After 4 to 5 days of incubation at 37°C in a CO₂-controlled humidified atmosphere, CEM, C8166 or Molt4/C8 giant (syncytium) cell formation was examined microscopically. The EC₅₀ (50% effective concentration) was defined as the concentration of compound required to inhibit HIV-induced giant cell formation by 50%.

Cytostatic activity assays

- 10 All assays were performed in 96-well microtiter plates. To each well were added $5 - 7.5 \times 10^4$ cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210) or 72 h (human lymphocyte CEM and Molt4/clone 8) at 37°C in a humidified CO₂-controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The IC₅₀ (50% inhibitory concentration) was defined as the
- 15 concentration of the compound that reduced the number of cells by 50%.

Discussion

A variety of glycopeptide antibiotic derivatives of vancomycin, eremomycin and teicoplanin including their aglycon derivatives were evaluated for their inhibitory activity against HIV-1(III_B) and HIV-2(ROD) in CEM cell cultures.

In contrast with vancomycin and eremomycin that did not show anti-HIV activity at 250 μM , the vancomycin derivatives 1 and 2 modified at X or Y (Scheme 1) were inhibitory to HIV-1 at an EC_{50} of 5.5 and 12 μM , respectively (Table 1). Whereas 2 was not inhibitory to HIV-2 at 50 μM , 1 showed an EC_{50} of 22 μM . The eremomycin derivative 5 proved very inhibitory to HIV-1 replication (EC_{50} : 0.43 μM) being cytotoxic against the CEM cells at a 100-fold higher concentration (IC_{50} : 40 μM). The other eremomycin derivatives 3 and 4 were at least 10-fold less inhibitory to HIV-1 than 5. No activity against HIV-2 at subtoxic concentrations was observed. Interestingly, the eremomycin aglycon derivatives 6 to 8 all invariably inhibited both HIV-1 and HIV-2 at EC_{50} values ranging between 3.5 and 12 μM . This is at compound concentrations that were at least 15- to 20-fold lower than required for the eremomycin aglycon. They were relatively non-toxic ($\text{IC}_{50} > 100 \mu\text{M}$ for CEM cells). The Des-(N-methyl-D-leucyl)-eremomycin aglycon 13 was also active against HIV (13-20 μM) and not toxic at 250 μM (Scheme 1, Table 1).

Antibiotic A40 926 derivatives 15 to 19 containing no N'-acyl substituent and mannose moiety at ring 6 (Scheme 2) also displayed anti-HIV-1 activity between 3.5 and 12 μM , with no or poor activity against HIV-2 at subtoxic concentrations (Table 1). These derivatives were also in general more cytotoxic to cell growth than vancomycin and eremomycin.

A large variety of teicoplanin aglycon derivatives have also been synthesized (Scheme 3) and evaluated for their anti-HIV activity (Table 1). All of them showed pronounced anti-HIV-1 and anti-HIV-2 activity, often with a trend of being slightly more active against HIV-1 than HIV-2. The most active congeners were inhibitory against HIV-1 in the range of 1.3 to 4.5 μM (compounds 20, 24, 26, 27, 30, 32, 36, 28, 40-45, 47 and 57). A number of them, i.e. 57, 36, 24, 20 were not cytotoxic at 100-500 μM . This means that the most selective compounds 24 and 36 had selectivity indices (ratio $\text{IC}_{50}/\text{EC}_{50}$) that were ≥ 200 . The antiviral activity of the latter compounds was also at least 10-fold improved over the unsubstituted teicoplanin aglycon (EC_{50} : 17-20 μM ; IC_{50} : $> 500 \mu\text{M}$).

Compounds 62 and 63 that lack the ring systems 1 and 3 and have only two macroring structures showed activity against HIV-1 and HIV-2 at an EC_{50} between 17 and 37 μM (Table

1, Scheme 4). Also, compound 64 (Scheme 5) showed an antiviral activity of 13 and 17 μM against HIV-1 and HIV-2, respectively (Table 1).

It is clear that in general, the aglycon derivatives of vancomycin, eremomycin and teicoplanin gain anti-HIV activity compared to their (usually inactive) glycosylated parent compounds. Also, substituents on the aglycons of vancomycin, eremomycin and teicoplanin that increase the lipophilicity of the aglycon derivatives, also markedly increase the anti-HIV activity of the compounds. In some cases, just the simple aglycon showed already measurable anti-HIV activity, but hydrophobic derivatives were, as a rule, markedly more (10- to 100-fold) inhibitory to HIV. Among the teicoplanin derivatives, both low hydrophobic and highly hydrophobic compounds showed prominent anti-HIV activity. The structural requirements to avoid cellular toxicity are unclear, but a number of antibiotic derivatives were clearly not cytostatic in cell culture, while retaining pronounced antiviral activity.

Seven compounds (6, 24, 35, 36, 40, 51 and 56) were evaluated against a variety of HIV strains in different cell lines, and it was found that they all maintained a similar antiviral potency regardless of the nature of the cell line or virus strain (Table 2).

A time of addition experiment was performed for the highly selective compound 35. Compound 35, like the virus adsorption inhibitor dextran sulfate, cannot be added later than 1 hr post infection without significant loss of antiviral activity. In contrast, administration of a reverse transcriptase inhibitor (AZT, zidovudine) could be delayed for at least 3 hours without losing its antiviral activity. These data point to a very early event in the replication (infection) cycle of HIV as the antiviral target for the novel antibiotic derivatives. In agreement with these observations, it is important noting that the compounds kept their antiviral efficacy against HIV-1 strains that contain mutations in the reverse transcriptase that result in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Table 3).

Extensive attempts (≥ 9 weeks) to select resistant virus strains against 20, 24 and 40 failed under experimental conditions that easily resulted in the emergence of nucleoside RT inhibitors (NRTI)- (i.e. lamivudine) or NNRTI- (i.e. nevirapine) resistant virus strains (data not shown).

In conclusion, novel classes of modified antibiotics have been discovered that were surprisingly active and selective against HIV in cell culture. The most active members of these antibiotic derivatives had an EC_{50} of 1-3 μM and were non-toxic in cell culture ($\text{IC}_{50} \geq 200$ -500 μM). Their antiviral mechanism of action is located at an early event in the infection cycle of

HIV (most likely adsorption and/or fusion), and is clearly different from the molecular mechanism of anti-bacterial activity. The compounds efficiently suppress drug-resistant HIV-1 strains, and resistance development in cell culture is difficult to engender. Therefore, the (lipophilic) aglycon antibiotic derivatives should be regarded as interesting new lead drugs that should be further explored as antiretroviral compounds for systemic use in the treatment of HIV infections. In addition, their early intervention in the infection cycle of HIV also make these compounds potential candidate drugs for prevention of HIV spread [i.e. as a microbicide when given locally (i.e. intravaginally)].

Table 1. Cytostatic and anti-HIV activity of glycopeptide antibiotic derivatives

Compound No.	IC ₅₀ ^a (μM)			EC ₅₀ ^b (μM)	
	L1210	Molt4/C8	CEM	HIV-1	HIV-2
Vancomycin	> 500	> 500	> 500	> 250	> 250
Eremomycin	500	> 500	> 500	> 250	> 250
Teicoplanin	> 500	> 500	> 500	18 ± 3.5	100 ± 0
Teicoplanin aglycon	> 500	> 500	> 500	17 ± 3.5	20 ± 0
Eremomycin aglycon	> 500	> 500	> 500	50 ± 28	250 ± 0.0
Vancomycin aglycon	> 500	> 500	> 500	65 ± 7.1	250 ± 0.0
1	53 ± 9	> 100	> 100	12 ± 3.5	22 ± 3.5
2	60 ± 8	53 ± 1	172 ± 15	5.5 ± 0.7	> 50
3	22 ± 0.3	24 ± 18	95 ± 14.1	5.1 ± 3.3	20
4	16 ± 6	33 ± 5	27 ± 7	7.0 ± 0	> 20
5	24 ± 0.4	17 ± 3	40 ± 4	0.43 ± 0.25	> 10
6	250 ± 39	> 500	> 500	5.5 ± 0.7	12 ± 3.5
7	84 ± 22	> 100	> 100	4.0 ± 0	3.5 ± 0.7
8	> 100	> 100	> 100	4.0 ± 1.7	5.5 ± 0.7
9	94 ± 15	126 ± 11	148 ± 3	1.6 ± 0.36	7.0 ± 0.0
10	> 250	> 250	> 250	41.7 ± 20.2	> 125

11	> 250	> 250	> 250	63.3 ± 53.5	> 125
12	> 250	> 250	> 250	7.5 ± 4.8	32.5 ± 3.5
13	> 250	> 250	> 250	13 ± 9.9	20 ± 7.1
14	> 250	> 250	> 250	7.3 ± 0.58	42.5 ± 10.6
15	44 ± 2.9	27 ± 14	32 ± 5.0	4.0 ± 1.4	> 10
16	20 ± 7.5	18 ± 2.5	80 ± 6.0	5.0 ± 0.7	> 10
17	36 ± 14	66 ± 20	> 250	12 ± 3.5	> 50
18	25 ± 0.7	35 ± 6.1	212 ± 54	3.5 ± 2.1	20
19	27 ± 0.3	22 ± 4.7	92 ± 5.0	3.5 ± 0.7	≥ 20
20	48 ± 8	> 100	> 100	1.4 ± 0.6	6.0 ± 3.9
21	19 ± 5	76 ± 8	389 ± 99	3.5 ± 0.7	5.5 ± 2.1
22	97 ± 4.3	> 100	> 100	8.0 ± 2.8	22 ± 3.5
23	15 ± 2	58 ± 11	140 ± 26	3.0 ± 1.4	5.0 ± 1.4
24	> 500	> 500	> 500	2.5 ± 0.7	8.0 ± 2.8
25	17 ± 9	58 ± 12	53 ± 11	4.5 ± 0.7	44 ± 1.4
26	43 ± 6	136 ± 33	179 ± 1	2.2 ± 0	6.5 ± 0.7
27	57 ± 15	182 ± 31	211 ± 1	1.3 ± 0.92	7 ± 0
28	5.7 ± 0.27	22 ± 22	58 ± 35	2.6 ± 2.0	5.5 ± 0.7
29	12 ± 6	41 ± 8	46 ± 8	4.0 ± 0	6.0 ± 0
30	175 ± 44	47 ± 4	113 ± 28	2.1 ± 1.3	5.0 ± 0
31	13 ± 0.4	36 ± 27	228 ± 91	5.0 ± 1.4	4.0 ± 1.4
32	9.1 ± 0.9	28 ± 0.4	18 ± 3	1.5 ± 0.42	2.3 ± 0.21
33	318 ± 256	> 500	> 500	3.5 ± 0.7	8.5 ± 2.1
34	26 ± 8.1	35 ± 8.2	> 250	4.5 ± 0.7	22 ± 3.5
35	29 ± 7	108 ± 79	> 500	3.0 ± 0	5.0 ± 1.4
36	61 ± 10	> 500	> 500	1.7 ± 0.42	3.0 ± 1.4
37	23 ± 7	35 ± 2	90 ± 27	5.5 ± 2.1	12.5 ± 3.5
38	51 ± 26	65 ± 1	74 ± 5	2.2 ± 0	7.5 ± 0.7
39	23 ± 11	68 ± 1	50 ± 8	2.7 ± 1.84	4.5 ± 0.7
40	10 ± 3	100	100	1.8 ± 0.49	7 ± 0
41	12 ± 0.1	73 ± 34	100	2.1 ± 0.14	4.2 ± 2.47

42	12 ± 2	19 ± 12	9.4 ± 1.9	1.6 ± 0.58	4.3 ± 0.58
43	51 ± 9	91 ± 13	> 100	2.1 ± 0.92	10 ± 0
44	7.3 ± 0.3	14 ± 3	14 ± 2	1.3 ± 0.21	1.3 ± 0.21
45	38.7 ± 3.4	32.3 ±	44 ± 0.42	1.5 ± 0.7	4.5 ± 2.1
46	> 500	> 500	> 500	15 ± 0	17.5 ± 3.5
47	38 ± 1	72 ± 6	66 ± 2	1.8 ± 0.49	7 ± 0
48	≥ 500	225 ± 8	402 ± 138	6.5 ± 0.7	12.5 ± 3.5
49	> 500	> 500	> 500	12.5 ± 3.5	25 ± 7
50	> 500	> 500	> 500	15 ± 7.1	17.5 ± 10.6
51	> 100	> 100	> 100	4 ± 0	7 ± 4.2
52	70 ± 23	> 100	> 100	6 ± 1	12 ± 5.2
53	> 100	> 100	> 100	9.7 ± 9	12.3 ± 6.8
54	22 ± 0.1	25 ± 0.99	104 ± 3.0	13 ± 9.9	6.0 ± 1.4
55	30 ± 5.7	26 ± 6.0	123 ± 6.0	7.0 ± 4.2	6.0 ± 1.4
56	212 ± 54	> 250	> 250	5.0 ± 1.4	17 ± 3.5
57	202 ± 68	> 250	> 250	2.5 ± 0.7	3.5 ± 2.1
58	92 ± 5	97 ± 10	106 ± 0	3.3 ± 1.4	7.5 ± 0.7
59	240 ± 15	≥ 250	> 250	9.0 ± 5.3	30.0 ± 7.1
60	91 ± 2	112 ± 2	125 ± 30	1.8 ± 0.58	7.0 ± 0.0
61	130 ± 1	132 ± 9	165 ± 34	6.0 ± 2.6	10.0 ± 2.8
62	95 ± 10	122 ± 13	240 ± 13	17 ± 3.5	11 ± 5.7
63	181 ± 4.0	> 250	> 250	17 ± 3.5	37 ± 18
64	73 ± 24	≥ 250	242 ± 11	13 ± 9.9	17 ± 3.5

^aIC₅₀, or compound concentration required to inhibit tumor cell proliferation by 50%.

^bEC₅₀, or compound concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures by 50%.

Table 2. Anti-HIV-1 and -HIV-2 activity of test compounds against different HIV-1 and HIV-2 strains and in different cell lines.

Compound No.	EC ₅₀ ^a (μM)							
	CEM/0							
	C8166 HIV-1(III _B)	MOLT4/C8 HIV-1(HE)	HIV-1(II _B)	HIV-1(HE)-	HIV-2(EHO)	HIV-1(MN)	HIV-2(RF)	
40	9.0 ± 4.2	7.5 ± 0.7	7.5 ± 3.5	17 ± 3.5	11 ± 1.4	12 ± 3.5	8.5 ± 2.1	
24	9.5 ± 3.5	9.0 ± 1.4	6.0 ± 1.4	12 ± 0.0	15 ± 0.0	13 ± 2.1	9.5 ± 3.5	
35	≥ 5	4.5 ± 0.7	2.8 ± 0.4	5.5 ± 0.7	11 ± 1.4	7.0 ± 0.0	3.7 ± 1.25	
36	6.6 ± 3.06	3.7 ± 0.35	2.8 ± 0.4	9.5 ± 3.5	6.8 ± 0.35	6.5 ± 0.7	3.7 ± 1.77	
56	-	25 ± 5.0	5.0 ± 1.4	40 ± 0.0	13 ± 6.6	25 ± 7.1	9.0 ± 4.2	
51	-	6.5 ± 4.3	4.0 ± 0	35 ± 7.1	35 ± 7.1	9.0 ± 1.4	10 ± 0.0	
6	-	22 ± 2.9	5.5 ± 0.7	40 ± 0.0	50 ± 0.0	20 ± 0.0	16 ± 5.7	

^a50% Effective concentration, or compound concentration required to inhibit HIV-induced cytopathicity by 50%.

Table 3. Anti-HIV-1 activity of test compounds against mutant HIV-1 strains in CEM cell cultures

Compound		EC ₅₀ ^a (μM)				
No.	HIV-1 III _B	Leu-100-Ile	Lys-103-Asn	Tyr-181-Cys	Tyr-188-His	
40	7.5 ± 3.5	12.5 ± 3.5	9.0 ± 1.4	10 ± 0.0	12.5 ± 3.5	
24	6.0 ± 1.4	11.5 ± 2.1	8.5 ± 2.1	7.5 ± 3.5	11.0 ± 1.4	
35	2.8 ± 0.4	6.0 ± 1.4	7.0 ± 0.0	10 ± 0.0	7.5 ± 0.7	
36	2.8 ± 0.4	5.3 ± 2.5	6.0 ± 1.4	8.5 ± 2.1	6.0 ± 1.4	
56	5.0 ± 1.4	24 ± 6.3	12 ± 0.0	9.5 ± 2.1	11 ± 6.4	
51	4.0 ± 0.0	-	17 ± 4.2	8.0 ± 0.0	-	
6	5.5 ± 0.7	-	11 ± 1.4	10 ± 0.0	-	

^a50% Effective concentration or concentration required to protect CEM cells against the cytopathicity of HIV by 50%.

Abstract

Glycopeptide Analogues

5

Novel classes of modified antibiotics have been discovered that were surprisingly active and selective against HIV in cell culture. The most active members of these antibiotic derivatives had an EC_{50} of 1-3 μM and were non-toxic in cell culture ($IC_{50} \geq 200-500 \mu M$). Their antiviral mechanism of action is located at an early event in the infection cycle of HIV (most likely

10 adsorption and/or fusion), and clearly different from its molecular mechanism of anti-bacterial activity. The compounds efficiently suppress drug-resistant HIV-1 strains, and resistance development in cell culture is difficult to afford.

15

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.